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Abstract 
 
            A wide range of antibacterial agents including antibiotics can be expelled out of 
the cell by AcrAB-TolC complex. In this complex, the membrane fusion protein AcrA is 
located in the periplasm and essential for drug efflux. Although AcrA is generally 
considered to be a physical linker that strengthens the weak interaction between the RND 
type transporter AcrB and the outer membrane channel TolC, the molecular mechanism 
of AcrA is still not well understood. To elucidate how AcrA functions in the multidrug 
efflux complex AcrAB-TolC, we characterized the structure of AcrA. Using the in vitro 
limited proteolysis approach, we demonstrated that both the N-terminal lipid 
modification and E. coli polar lipids affect the accessibility of AcrA to trypsin. In addition, 
we found that the cleavage sites are located in the conserved membrane proximal (MP) 
domain of AcrA. We next used these sites as a map to characterize the structure of AcrA 
in the periplasm. Our in vivo study showed that the overall structure of over-expressed 
AcrA in vivo is similar to that of the purified AcrA. However, the trypsin cleavage of the 
chromosomally encoded AcrA demonstrated that the tripartite AcrAB-TolC assembly 
protects the MP domain of AcrA. This result thus suggests that the MP domain of AcrA is 
required for the functional assembly of the multidrug efflux complex AcrAB-TolC.  
            The oligomeric state of AcrA is still uncertain. Here we used formaldehyde cross-
linking and size exclusion chromatography to study the oligomerization of AcrA. We 
found that, in contrast to the monomeric form of soluble AcrA (AcrAS-His), the lipidated 
AcrA (AcrAL-His) exists as an oligomer, mostly as a trimer. This result indicates that 
lipid modification promotes oligomerization of AcrA. In addition, soluble AcrA can form 
xiv 
 
an oligomer in the presence of E. coli polar lipids and low concentrations (less than 100 
mM) of sodium chloride, suggesting that AcrA-lipid interaction is one of the driving 
forces for the oligomerization of soluble AcrA. We concluded that AcrA functions as an 
oligomer, possibly a trimer.  
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I. Introduction 
 
I.1 AcrAB-TolC is the major multidrug efflux complex in E. coli 
            Antibiotics are the powerful means with which human beings combat bacterial 
infections. Although many antibiotics are still widely used and new antibiotics are 
developed, drug resistance in bacteria attracts more and more attention. Particularly, 
Gram-negative bacteria are more resistant than Gram-positive bacteria (46). Both low 
permeability of the unique outer membrane and  drug efflux systems in Gram-negative 
bacteria contribute to drug tolerance in clinical isolates (31). Compared to the substrate-
specific transporters, multidrug efflux transporters are capable of expelling many 
structurally unrelated compounds including antibiotics, dyes, detergents, organic solvents, 
bile salts, to the outside medium. Moreover, exposure to antibiotics can induce the over-
expression of otherwise silent multi-drug efflux transporters (45).  
           Based on energy sources, multidrug-efflux pumps are classified into: primary 
transporters belonging to the ATP-Binding Cassette (ABC) family of proteins, which 
expel substrates at the expense of hydrolysis of ATP, and secondary pumps that utilize 
transmembrane electrochemical potential of proton or sodium ion as the driving force 
(53). These secondary transporters belong to four superfamilies of proteins: Major 
Facilitator Superfamily (MFS), Resistance-Nodulation-cell Division (RND) superfamily, 
Multidrug And Toxic compound Exporters (MATE), and Small Multidrug Resistance 
(SMR) family (53).  
            The majority of multidrug efflux transporters in Gram-negative bacteria belong to 
the RND superfamily (52). Seven ORFs (acrB, acrD, acrF, yhiV, cusA, yegN and yegO) 
2 
 
on the chromosomal DNA of E.coli are assumed to be capable of drug transport (47). 
However, only AcrAB-TolC is over-expressed in clinical isolates (39).  
            RND transporter AcrB in E. coli takes advantage of influx of protons (from 
periplasm to cytoplasm) to expel the drugs to the external medium. AcrB functions in 
conjunction with two accessory proteins: Outer-Membrane Factor (OMF) TolC and the 
periplasmic adaptor protein, AcrA (11, 37). The essential role of these components in the 
multidrug efflux was confirmed by the increased susceptibility to antibiotics with the 
deletion of any components in this complex (48). Bypassing the periplasm, AcrA-AcrB-
TolC complex extrudes various substances directly into the external medium (66). The 
substrates include, but are not limited to, chloramphenicol, fluoroquinolones, fusidic acid, 
lipophilic β-lactam antibiotics, nalidixic acid, novobiocin, rifampin, tetracycline, 
acriflavine, ethidium bromide, bile salts, short-chain fatty acids, SDS, Triton X-100 (TX) 
and triclosan (51). 
            Biochemical studies showed the interactions between the components in this 
tripartite complex. AcrA interaction with AcrB and/or TolC was demonstrated in the in 
vivo and in vitro studies (14, 23, 66, 67, 74). Dithiobis(succinimidylpropionate) (DSP) 
cross-linking in vivo showed that AcrA associates with AcrB independently of TolC and 
substrates (74). A chimeric study further implied that the C-terminal residues of AcrA 
(290-357 a.a) are involved in the interaction with AcrB (7). Another independent study, 
Isothermal Titration Calorimetry (ITC) experiments, also illustrated that the C-terminal 
domain of AcrA (172-397 a.a) binds to AcrB (67). The interface of AcrA-AcrB was 
mapped in the recent in vivo site-specific cross-linking study (62). It showed that 
contiguous β-roll, β-barrel, and lipoyl domain of AcrA are physically adjacent to the 
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periplasmic domain of AcrB (62). On the other hand, AcrA interaction with TolC was 
demonstrated in several genetic and biochemical studies (14, 23, 32, 66, 67). Cross-
linking of cysteine residues introduced by site-directed mutagenesis into AcrA and TolC 
implied that the AcrA-TolC interaction domain is located between residues on the lower 
α-helical barrel domain of TolC and the N-terminal α-helix of the AcrA coiled-coil (32). 
Although a cross-linking study showed that AcrB and TolC are spatially adjacent to each 
other (63), it is generally assumed that interaction between AcrB and TolC is weak, 
especially in the absence of AcrA (66).  
            On the other hand, structural studies of these three proteins in recent years greatly 
enhanced our understanding of the complex formation at the molecular level. Crystal 
structures of TolC, AcrB and AcrA were released in 2000, 2002, and 2006, respectively 
(28, 40, 43).  
            As shown in Figure I.1, the crystal structure of the OMF TolC is a cannon-like 
trimer with a length of about 140 Å (28). This trimer can be further divided into an outer 
membrane section and a periplasmic section. Four strands from each protomer assemble 
and form a 40 Å thick, 12-stranded β-barrel that crosses the outer membrane. The 
periplasmic section comprises the 100 Å long α-helical barrel and equatorial section 
surrounding the helical domain. The proline-containing interdomains link the right-
handed β-barrel and left-handed α-helical barrel. Unlike the partially or fully occluded 
interior of some outer membrane proteins (5, 8, 33, 49, 57), the top of the structure, or the 
outer membrane section of TolC, is open and fully accessible to solvent. Nevertheless, the 
bottom of the α-helical barrel is closed by coiled-coils in this structure.  
            In the crystal structure, the RND pump AcrB is arranged as a jellyfish-like trimer  
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Figure I.1 Crystal structure of TolC (28). The individual protomers are colored blue, red, 
and yellow. The β-barrel domain of TolC transverses the bacterial OM.  
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Figure I.2 Crystal structure of AcrB (43). (A) Side view of a ribbon representation of 
three protomers, which are individually coloured (blue, green and red). (B) A cutaway 
view displaying the solvent-accessible surface of AcrB. The framework of the funnel and 
the cavity are indicated by dotted lines. The yellow areas of the surface are coloured 
according to residues from Asp 99 to Leu 118 in pore helices. The pale green areas are 
coloured according to residues in TM7 (Gly 539–Val 557) and TM8–TM9 (Ser 869–Phe 
918). 
A 
B 
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 (Figure I.2) (42, 43, 58). It consists of a 50 Å transmembrane domain and a 70 Å 
periplasmic headpiece. This headpiece can be further divided as an upper TolC-docking 
domain and a lower pore domain with 30 and 40 Å thick, respectively. The trapezoidal 
TolC-docking part is about 70 Å wide at the bottom and 40 Å wide at the top. The 
cutaway view showed that this TolC-docking domain is a funnel-like structure which 
opens to the outside. The maximal inner diameter of this domain is about 30 Å. In 
addition, a long hairpin from the TolC-docking domain in each protomer inserts into the 
upper part in the next protomer, which possibly results in the tight packing of the 
headpiece in periplasm. Three α helices from each protomer, nine helices in total, form 
the pore domain. The bottom part of the pore domain is open to form the central cavity, 
which is supposed to mediate substrate trapping from periplasm. Loosely packed 
transmembrane domains are organized in a ring-like structure with a central hole. The 
site-specific mutagenesis studies (17, 43) show that there are three essential charged 
residues: Asp 407, Asp 408 and Lys940 in this transmembrane domain. These three 
residues are proposed to mediate the proton translocation through the inner membrane.  
            The protease-resistant fragment of AcrA (45-312 a.a) was crystallized and the 
core portion (53-299 a.a) was solved in 2006 (40). The protomer structure of AcrA is 
similar to that of MexA (1, 21), a homologous membrane fusion protein in P. aeruginosa. 
Both AcrA and MexA have the elongated sickle shape protein structures. The resolved 
structure displayed three domains: a β-barrel domain, a coiled-coil α-helical hairpin and a 
lipoyl domain between above two domains (Figure I.3 A). This result is consistent with 
the secondary structure prediction based on the amino acid sequence: helices domain, 
lipoyl domain and C-terminal hydrophobic domain (26). The β-barrel domain consists of  
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Figure I.3 Crystal structure of membrane fusion proteins. (A) Structure of AcrA (45–
312)-4M (molecule C) (40), with the α-helical hairpin domain in red, lipoyl domain in 
green, and β-barrel domain in cyan. (B) Completed structure of the MexA including the 
MP domain (62). The α-hairpin domain, lipoyl domain, β-barrel domain, and MP domain 
are colored blue, green, yellow and orange, respectively. 
 
 
 
 
 
A B 
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Figure I.4 Docking model of AcrAB-TolC (62). The surface rendering of the AcrA3-
AcrB3-TolC3 complex is colored by its components. The TolC trimer (orange, red, and 
yellow subunits with gray equatorial domains and membrane regions) is docked onto the 
AcrA (green)-docked AcrB trimer (blue/light blue subunits with gray membrane regions). 
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six antiparallel β-strands and a short α helix. The lipoyl domain includes two lipoyl half-
motifs, each of which comprises four β-strands. These two half motifs interwine with one 
another to form a β-sandwich. The α-helical domain is composed of two helices linked by 
a loop. Compared to four heptad repeats in MexA (1, 21), each helix in AcrA includes 
five heptad units, which accounts for the length difference between AcrA (105 Å) and 
MexA (89 Å). More recently, the crystal structure on the N- and C-termini of MexA was 
recently reported (62). As demonstrated in Figure I.3 B, these ninety two residues at the 
termini (residues 13-27 and 262-339) form a compact β-roll extending from the β-barrel 
domain on a β-ribbon linker. Since this β-roll is adjacent to the inner membrane, it was 
named the membrane proximal (MP) domain. Given the high sequence similarity 
between MexA and AcrA, AcrA possibly assumes the similar structure as MexA, 
including four domains: β-barrel domain, coiled-coil α-helical hairpin, lipoyl domain and 
MP domain.  
            The arrangement of the complex was investigated by superimposing crystal 
structures of AcrB and TolC and several models have been proposed (6, 9, 62). Of them, 
the appealing molecular docking model is based on the cross-linking experiments with 
AcrA-TolC and AcrA-AcrB (62), showing that these three proteins form a tripartite 
AcrA3-AcrB3-TolC3 complex (Figure I.4) (62), in which α-helical hairpins of AcrA are 
rotated to bind on the TolC entrance coiled coils, while the lipoyl domain, β-barrel 
domain, and MP domain bind to AcrB. In addition, there is a close fit between the top 
section of AcrB and the bottom section of TolC.  
            Despite the fact that more and more biochemical and biophysical (structural 
analysis) information about the tripartite complex reveals the interactions between 
10 
 
components, some open questions are still awaiting answers. For example, what is the 
stoichiometry of the interacting components, especially the oligomeric number of AcrA? 
Does AcrA interaction with AcrB and/or TolC induce conformational changes of AcrA? 
and if yes, how do these conformational changes coordinate with drug efflux? 
 
I.2 AcrA, the periplasmic membrane fusion protein, is anchored into the inner 
membrane by lipid modification 
            There are 397 amino acid residues in AcrA from E. coli. Like other lipoproteins in 
the periplasm (24), AcrA has a characteristic signal peptide at the N-terminus (24 residues) 
shown below (40):  
 
 
in which the N-terminal domain (n) includes two positively-charged residues, followed 
by the hydrophobic h-region and a lipobox from -3 to +1 position. This signal peptide 
directs AcrA translocation into periplasm (38). The studies of bacterial lipoprotein 
biosynthetic pathways in the 1970s elucidated the lipid modification of lipoproteins in 
periplasm (19). According to this theory, the thiol group and the N-terminal amido 
linkage of cysteine residue just outside the signal peptide in lipoproteins are modified to 
covalently link diacyglyceryl and acyl respectively, thereby anchoring matured 
lipoproteins into the inner membrane. The final composition of the N-terminal cysteine 
residue is shown in Figure I.5 A (19). 
            Detailed studies indicate that there are three sequential steps during this chemical 
 
     + + 
mnknrgftplavvlmlsgslaltgc 
   n                 h                   lipobox  
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A 
              
B 
                      
Figure I.5 Lipid modification at N-terminal Cys residue. (A) Chemical structure of 
modified cysteine residue (19). The diacylglyceryl group covalently attaches cysteine 
residue via thioether linkage, whereas the N-terminal amido linkage is modified to link 
fatty acyl group. (B) Biosynthetic pathway of lipid modification of lipoproteins (56). 
Three sequential steps are catalyzed by three enzymes. 
12 
 
modification: first, the thiol group in the side chain of cysteine residue is subject to 
diacylglyceryl modification, which is catalyzed by the enzyme diacylglyceryl transferase 
(30, 56). Second, the signal peptidase II cleaves at the amido site between cysteine 
residue and signal peptide (8, 24), thus removing the signal peptide and exposing the 
amino group of the cysteine residue. Third, this free amino group is acylated by fatty acid 
with the aid of transacylase (18, 55). These three steps are illustrated in Figure I.5 B (56).  
            Given that the first 24 amino acids of AcrA show features typical of a signal 
peptide of bacterial lipoproteins, AcrA is subject to this kind of lipid modification (40). 
This lipid modification of AcrA was experimentally confirmed by labeling cells with 
radioactive palmitic acid (72). This lipid modification at the N-terminus of AcrA results 
in association with the inner membrane. On the other hand, mutation of cysteine residue, 
regardless of deletion and substitution, abolished the membrane anchoring and made 
AcrA as well as the homologous MexA in P. aeruginosa soluble in an aqueous medium 
(70, 72). The functional roles of this lipid modification in AcrA and MexA were also 
studied. In particular, original signal peptides of AcrA and MexA were replaced with 
cleavable but non-lipidated OmpA and Azurin signal peptides, respectively (70, 72). The 
minimal inhibitory concentrations (MIC) of these soluble AcrA (OmpA-AcrA) and MexA 
(Azurin-MexA) are almost the same as the corresponding lipoproteins, indicating that this 
lipid modification is not required for drug extrusion.  
 
I.3 Conformational flexibility of AcrA 
            Since AcrA is located in periplasm and functions as an adaptor protein to bridge 
AcrB and TolC, it is very interesting to know whether AcrA has structural flexibility and 
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how the conformational changes of AcrA coordinate with the drug transport by AcrB 
and/or TolC channel opening. Electron Paramagnetic Resonance (EPR) analysis of spin-
labeled AcrA mutants demonstrated conformational changes of AcrA induced by acidic 
pH (25). When pH of buffer was changed from 7.0 to 5.0, AcrA was subject to substantial 
reversible structural changes at residue 62 (lipoyl domain) and residues 103, 146 and 172 
(α-helical hairpin domain). Moreover, local protein structure in close proximity of these 
residues underwent conformational changes and thus these residues are in a more 
restricted environment under pH 5.0. On the other hand, in the solved X-ray crystal 
structure, four conformations of AcrA in the asymmetric unit illustrate that the structural 
changes are due to hinge flexibility between lipoyl domain and α-helical hairpin (40). 
Figure I.6 shows the superposition of AcrA monomers in which the maximal angle 
change of the hinge linker is 15 degrees (21 Å in distance) based on the lipoyl domain. 
This hinge-like conformational flexibility at the base of the α-helical domain in AcrA 
possibly contributes to assembly of the efflux complex and energy transition from AcrB 
to TolC, which is postulated to be involved in the iris-opening of the TolC. In contrast, 
there are no such changes in MexA crystal structure, although the molecular simulation of 
MexA suggested similar inter-domain motion (68).                                                                     
            In addition, heterogeneity of the sedimentation coefficient and polydisperisity 
parameter from Dynamic Laser Scattering (DLS) of AcrA implied that AcrAs without Mg 
cation adopt two conformations compared to the one dominant conformation in the 
presence of magnesium (72). This conformational transition is not due to the secondary 
structure change based on the similar circular dichroism spectra data.  
            The   above  in  vitro   studies   showed  the  conformational   flexibility  of  AcrA,      
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Figure I.6 Conformational flexibility of AcrA. Comparison of four conformations of 
AcrA (45-312)-4M observed in the crystal (40), with molecules A, B, C, and D 
superposed on the lipoyl domain. The greatest difference, ~15°, is between molecules B 
and C.  
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indicating that, rather than a passive linkage between AcrB and TolC, AcrA is a dynamic 
protein and actively participates in the drug efflux across both periplasm and outer 
membrane. One of the remaining questions in this field is how these conformational 
changes of AcrA coordinate with the efflux process.  
 
I.4 Oligomerization of AcrA in vivo and in vitro 
            Unlike the integral membrane proteins such as trimers of AcrB and TolC, 
oligomerization of AcrA is still unclear: what is the “functional” oligomeric number of 
AcrA in vivo? How do the oligomers of AcrAs assemble with the two other components 
of the complex and mediate multidrug extrusion?  
           A hydrodynamic analysis was used to determine the oligomeric state of soluble 
AcrA (OmpA-AcrA-His) in vitro. A sedimentation equilibrium study indicated that this 
soluble AcrA exists as  a monomer in solution (72). Moreover, the sokes radii calculated 
from sedimentation and Dynamic Laser Scattering showed that the axial ratio of AcrAS-
His is about 8, suggesting that the AcrAS-His is an asymmetric elongated molecule. 
Similarly, most of non-lipidated MexA was shown to be monomer, although a small 
amount of dimer was detected in gel filtration experiment (1). Interestingly, an electron 
paramagnetic resonance study showed that acidic pH results in oligomerization of AcrAS-
His in solution. Disulfide cross-linking showed that AcrAS-His oligomers are arranged in 
parallel (25).  
            In another independent study, AcrAS-His was crystallized on lipid layers 
containing nickel-chelating phospholipid DOGS-NTA (2). In this experiment, AcrA was 
attached by the C-terminal 6His tag. Electron crystallography showed the two-
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dimensional structure of AcrA at 30 Å level as layer group P2122. There are four 
asymmetric units in the unit cell, including two tubular rings with about 150 Å in 
perimeter and a hole of approximately 30 Å in diameter. The contour length of a quasi-
helical path is about 210 Å, which is very consistent with the length data from the 
hydrodynamic study (72). In contrast to the three-fold symmetry structure of the 
inner/outer membrane components (AcrB and TolC) (29, 45), this horse-shoe structure of 
AcrA is likely a dimer configuration.   
            Interestingly, the core portion of AcrA (45-312 a.a) was reported to assemble as a 
dimer of dimers in the X-ray crystal structure (40). Anti-parallel dimerization involves 
inter-molecular helix interaction (Figure I.7 A). The C-terminal helix from one monomer 
interacts with the adjacent N-terminal helix from a second monomer in classical knobs-
into-holes packing manner. On the other hand, two parallel AcrA monomers extensively 
interact through α-helical hairpins, lipoyl domain and β-barrel domains. It should be 
noted that X-ray crystallography here only shows the central part of AcrA. About one 
third of the protein residues at both termini are missing in the protease-resistance core of 
AcrA. The 28 N-terminal and 98 C-terminal residues of the AcrA were not resolved. Thus, 
the crystal structure here does not provide the whole picture of AcrA. Although the MP 
domain of MexA was recently resolved (62), further experiments are needed to confirm 
the similar domain in AcrA and check the oligomerization status of the complete structure 
of AcrA. 
            Chemical cross-linking has been carried out to determine the oligomerization of 
AcrA, with and without lipid modification in vivo (74). It showed that lipidated AcrA 
forms oligomers, possibly trimers (Figure I.7 B). Unlike the monomeric status of AcrAS-
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His in solution, the in vivo cross-linking demonstrated that AcrAS-His also forms 
oligomers, possibly as trimers (74). Furthermore, oligomerization of AcrA in strains with 
different genetic backgrounds was not affected by the existence of other two components, 
AcrB and TolC, indicating that AcrA oligomerization is independent on AcrB and/or TolC.  
            In addition, oligomerization of AcrA homologs has also been investigated. For  
example, in X-ray crystal structures, central parts of MexA form a tridecamer (1, 21). The 
six-subunit-assembly and the seven-subunit-assembly in parallel manner are organized in 
the head-to-head manner. However this arrangement of MexA could not fit with AcrB 
and TolC in complex assembly. In addition, oligomers including nine or six subunits in 
parallel manner have also been proposed (1, 21, 59). Another membrane fusion protein, 
MacA from the ABC type transporter complex MacAB-TolC, was recently crystallized 
(50). The X-ray crystal structure demonstrated that MacA exists as a hexamer, which is 
further confirmed by electron microscopy and gel filtration results (71). Additionally, 
trimers are dominant in the cross-linking analysis of another MFP HylD (64). Gel 
filtration of EmrA shows equilibrium of monomer, dimer and trimer in solution and this 
oligomerization is concentration-dependent (4). 
            Taken together, current studies showed different oligomerization status of AcrA as 
well as its homologs. Oligomerization transitions due to the change of pH and 
concentration demonstrated a dynamic nature of oligomerization of AcrA. It is thus likely 
that more biochemical and biophysical studies, for instance, the X-ray crystallography of 
the efflux complex AcrAB-TolC, are needed for deep insight into the molecular 
mechanism of AcrA oligomerization and further understanding of the functional complex 
assembly.   
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Figure I.7 Oligomers of AcrA. (A) Dimer of dimers of AcrA in the X-ray crystal 
structure (40). Ribbon representation of AcrA (45-312)-4M demonstrates two apparent 
dimers per asymmetric unit in the crystal. The protomers are shown in red, pink, blue, 
and green. (B) Oligomers of AcrA in vivo (74). Dimers and trimers of AcrA are visualized 
by disuccinimidyl glutarate (DSG) cross-linking in vivo. The oligomerization of AcrA is 
independent of AcrB (AG102MB is ∆acrB) and TolC (ZK796 is ∆tolC). 
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II Materials and Methods 
 
II.1 Bacterial strains and plasmids, media and growth conditions  
            All strains and plasmids used in this study are listed in Table II.1. E. coli strains 
were grown at 37°C in Luria-Bertani (LB) broth (10 g of Bacto tryptone, 5 g of yeast 
extract, and 5 g of NaCl per liter). Antibiotics were added when needed to the following 
final concentrations: ampicillin (100 µg/ml), kanamycin (34 µg/ml), spectinomycin (50 
µg/ml), tetracycline (25 µg/ml), and chloramphenicol (25 µg/ml).  
 
II.2 Purification of AcrA, AcrB and TolC by affinity chromatography 
            Unless indicated otherwise, we use superscript “L” to stand for lipid modification, 
and superscript “S” to highlight the soluble periplasmic AcrA without lipid modification. 
To purify AcrAL-His containing the N-terminal lipid moiety (AcrA-6His), AG100AX E. 
coli cells (∆acrAB ∆acrEF) containing plasmid pAcrAHis were grown overnight and re-
inoculated into 500 ml fresh LB medium supplemented with ampicillin. The expression 
of protein was then induced by 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
when cultures reached OD600 ~0.5-0.7. After three hours induction, cells were collected 
by low speed centrifugation (3,220 x g, 30 min) and resuspended in buffer containing 20 
mM Tris-HCl (pH 8.0), 1 mM EDTA, and 1 mM PMSF.  Lysozyme was added to final 
concentration of 100 µg/ml and incubated on ice for 30 min. Cells were broken by 
sonication, the unbroken cells were removed by low speed centrifugation at 3,220 x g for 
15 min, and the supernatant was further centrifuged at 50,000 x g for 1 hr. The membrane 
pellet was resuspended in 20 mM Tris-HCl (pH 8.0) buffer containing 500 mM NaCl, 5 
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Table II.1 List of strains and plasmids  
Strains and 
plasmids 
Description Source/references 
E. coli strains   
   AG100 K-12 argE thi-1 rpsL xyl mtl galK supE441-
∆(gal-uvrB)λ- 
(13, 48) 
   AG102MB argE3 thi-1 rpsL xyl mtl galK supE441-∆(gal-
uvrB)λ:: 
H. Nikaido 
   ZK796 Tetr, same as MC4100 but tolC::Tn10 (15) 
   AG100AX argE3 thi-1 rpsL xyl mtl galK supE441-∆(gal-
uvrB)λ- ∆acrAB::kan ∆acrEF::spe 
(41) 
   ECM2112 MC4100 but ∆acrAB::kan  tolC::Tn10 Lomoskaya, O 
   
Plasmids   
    pUC18 E. coli cloning vector, Ampr - 
    pUC151A pUC 18 vector carrying the acrAB genes (38) 
    pBP184 pACYC184 vector, Cmr, expressing acrB under 
native promoter 
(25) 
    pAcrAHis His6-tagged acrA derivative of pUC151A 
plasmid  
Zgurskaya H.I. 
    
pAcrAHisAcrB 
His6 between acrA and acrB derivative of 
pUC151A plasmid 
Zgurskaya H.I. 
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    pAcrBHis His6-tagged acrB derivative of pUC151A 
plasmid 
(66) 
    pTolCHis His6-tagged tolC derivative of pTrc99A-TolC 
plasmid  
(66) 
    pUZ11 pUC18 vector carrying the ompA-acrA-His 
fusion sequence under lac promoter 
(72) 
pUZ11 
(A30C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A30C) 
(25) 
pUZ11 
   (A39C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A39C) 
(25) 
pUZ11 
    (A62C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A62C) 
(25) 
   pUZ11 
    (A103C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A103C) 
(25) 
    pUZ11 
    (A146C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A146C) 
(25) 
    pUZ11 
    (A172C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A172C) 
(25) 
    pUZ11 
    (A204C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A204C) 
(25) 
    pUZ11 
    (A242C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A242C) 
(25) 
    pUZ11 pUC11 derivative carrying single mutation in (25) 
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    (A295C) ompA-acrA-His  (A295C) 
    pUZ11 
    (A339C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A339C) 
(25) 
    pUZ11 
    (A390C) 
pUC11 derivative carrying single mutation in 
ompA-acrA-His  (A390C) 
(25) 
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mM imidazole and 1mM PMSF, then an equal volume of 10% TX in binding buffer was 
slowly added and incubated overnight at 4°C. The insoluble material was removed by 
centrifugation at 50,000 x g for 1 hr. Solubilized membrane proteins were loaded onto 
Cu2+ charged NTA column equilibrated with 20 mM Tris-HCl (pH 8.0) binding buffer 
containing 500 mM NaCl, 5 mM imidazole, 1 mM PMSF, and 3.2 mM TX. The column 
was washed twice, first with the above binding buffer, then the same buffer but 
containing 60 mM imidazole. Bound AcrA was eluted with the elution buffer containing 
500 mM imidazole and 3.2 mM TX. Purified AcrA was dialyzed against buffer 
containing 20 mM Tris-HCl (pH 8.0), 200 mM NaCl, 3.2 mM TX, and 1 mM EDTA and 
stored at 4°C until needed. For prolonged storage, dialysis buffer was supplemented with 
50% glycerol (v/v) and protein was stored at -20°C. 
            The purification of AcrB-His protein was performed as described previously (66, 
73). The plasmid pAcrBHis was transformed into AG100AX cell. The same purification 
steps were used as described fro the AcrAL-His protein. The plasmid pTolCHis was 
transformed into AG100AX cells to purify TolC-His protein. A similar purification 
protocol was followed with modifications in buffer compositions (66). In particular, after 
the binding buffer wash, an imidazole gradient of 60 mM and 500 mM with equilibration 
buffer containing 0.5% polyoxyethylene (POE) was used for the consequent washes.  
Purified TolC was eluted in 500 mM imidazole fractions. This fraction was dialyzed to 
remove imidazole, and kept in storage buffer containing 20 mM Tris-HCl (pH 7.4), 500 
mM NaCl, 5 mM MgCl2, 1 mM PMSF, 0.5% POE and 50% glycerol. 
            A similar purification protocol was followed to purify AcrAS-His with 
modifications in buffer composition and membrane solubilization. Plasmid pUZ11 was 
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transformed into AG100AX cells. Cells were lysed in same 20 mM Tris-HCl (pH 8.0) 
buffer but without EDTA.  The protein was purified as described by previous study (72). 
 
II.3 SDS-polyacrylamide gel electrophoresis analysis 
            Protein samples were analyzed with sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins samples were mixed with sample buffer (0.25M 
TrisCl pH 6.8, 8% SDS, 10% glycerol, 5% β-mercaptoethanol and bromophenol blue) 
and resolved by SDS-PAGE (8% or 12% [wt/vol] acrylamide). Protein bands were 
visualized with Coommassie Brilliant Blue (CBB) or silver nitrate staining (20). For 
immunoblotting, proteins were transferred electrophoretically to polyvinylidene difluoride 
(PVDF) membrane (Immobilon, Millipore) in 3-(cyclohexylamino)-1-propanesulfonic acid-
NaOH (10 mM, pH 11.0) and methanol (10%), and proteins were visualized using anti-AcrA 
polyclonal antibody and alkaline-phosphatase-conjugated anti-rabbit antibody (Sigma). 
 
II.4 Fluorescence labeling of AcrA in vivo and in vitro 
            E. coli cells carrying plasmids expressing AcrA-Cys variants were grown to 
OD600 ~0.5-0.7 and then induced with 0.1mM IPTG. Three hours after induction, cells 
were harvested using low speed centrifugation (3,220 x g, 30 min), and then washed with 
standard Phosphate Buffered Saline (PBS) (pH 7.4) buffer. Labeling of whole cells (in 
vivo) was done in PBS (pH 7.4) buffer containing 100 µM of fluorescein-5-maleimide 
(F5M). After incubation with F5M for 30 min at room temperature (RT), the labeling 
reaction was stopped by addition of the excess of DL-Dithiothreitol (DTT, 5mM). Cells 
were washed with PBS buffer to remove F5M and resuspended in the binding buffer 
including 20mM Tris-HCl (pH 7.5), 5mM imidazole, and 500mM NaCl. After pre-
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treatment with lysozyme (100 µg/ml, 20min on ice), cells were sonicated (Branson 450 
Sonifier). Unbroken cells were removed by low speed centrifugation (3,220 x g for 15 
min) and AcrA variants were purified using metal-affinity chromatography as described 
above. Then, purified, labeled proteins were resolved on SDS-PAGE (10%) and 
fluorescence was detected using Storm 840 Imager (Molecular Dynamics) using the 
excitation wavelength 450 nm and the emission wavelength 520 nm. To visualize proteins 
and compare their amounts, after fluorescence scanning gels were stained with CBB. 
Fluorescence intensity and protein amount were analyzed using the ImageQuant™ TL 
program (Amersham Pharmacia). For each protein band the fluorescence intensity was 
normalized on the protein amount determined from the same gel after staining with CBB. 
The largest normalized fluorescence intensity was set as 100% and used to obtain the 
relative fluorescence intensity for each band. 
For in vitro labeling, cells were lysed and AcrA was purified using affinity 
chromatography described above. After protein purification, labeling with F5M (20µM) 
was carried out for 30 min at RT. Reactions were terminated and fluorescence and 
amounts of proteins were analyzed as described above. 
 
II.5 Limited proteolysis assay (trypsin and proteinase K) 
            Purified AcrA was incubated with trypsin at 19.5:1 molar ratio of AcrA:trypsin or 
200: 1 molar ratio of AcrA:PK. For proteolysis in the presence of lipids, the polar 
fraction of E. coli lipids (Avanti Polar Lipids) was re-suspended to final concentration 10 
mg/ml by sonication in buffer containing 20 mM Hepes (pH 7.0 or pH 6.0) and 100 mM 
NaCl. When needed TX was added to final concentration 3.2 mM. Purified AcrA was 
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mixed with lipids in amounts indicated in Figures and incubated for 20 min at room 
temperature. Tryptic digestion was carried out at 37°C. Aliquots were withdrawn at 
different time points, and reactions were terminated by boiling in the SDS-PAGE sample 
buffer and analyzed by SDS-PAGE followed by silver nitrate staining. 
 
II.6 Reconstitution of proteins into proteoliposomes (“PL”) 
            Reconstitution was done according to previous studies (9, 28). E. coli polar lipid 
extract (Avanti) was sonicated in reconstitution buffer containing 20 mM Hepes (pH 7.0), 
5 mM DTT to final concentration 40 mg/ml. TX was then added to final concentration 
0.45% (wt). Protein was slowly added to lipid detergent solution at 1:200 (wt) of 
protein:lipids ratio and the sample was then incubated at RT for 30 min. After the 
pretreatment with methanol, water and reconstitution buffer in sequence, SM-2 Adsorbent 
Bio-Beads (Bio-Rad) were used to remove TX: two times of one-hour incubation at room 
temperature, and then one-hour incubation at 4°C. Reconstituted proteoliposomes were 
pelleted by high speed centrifugation (250,000 x g, 1 hr, 4°C) using TLA 100.3 rotor 
(Beckman). The proteoliposome pellet was resuspended in buffer including 20 mM 
Hepes (pH 7.0), 0.1 mM DTT, and 50 mM KCl. The PL samples along with bovine 
serum albumin (BSA) standards were then resolved on SDS-PAGE (12%) and stained 
with CBB. Gels were scanned and the intensity of each protein band was quantified using 
ImageQuant® program (Molecular Dynamics).   
 
II.7 Identification of AcrA tryptic fragments by MALDI-TOF mass spectrometry 
            AcrA was digested with trypsin at a 19.5 molar ratio of AcrA/trypsin at 37ºC for 
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90 min. The reaction was terminated by addition of acetic acid to final concentration 2%. 
Ziptip C18 and C4 (large fragments) (Millipore) were used to desalt and concentrate 
tryptic fragments of AcrA. AcrA fragments were eluted using an aqueous solution 
containing 50% of acetonitrile and 0.1% trifluoroacetic acid. MALDI-TOF analysis was 
carried out at the Molecular Biology-Proteomics Facility, University of Oklahoma Health 
Sciences Center. Samples were mixed with sinapinic acid (3,5-dimethoxy-4-hydroxy-
cinnamic acid) and then spotted and dried on specimen grids. MALDI-TOF Mass spectra 
of peptide fragments were collected in the linear mode on a Voyager-DE Pro mass 
spectrometer (Applied Biosystems) equipped with a delayed extraction device. 
 
II.8 Size exclusion chromatography (SEC) in conjunction with light scattering (LS) 
and refractive index (RI) measurements 
            Light scattering refers to a process in which light from an incident polarized laser 
beam is scattered in all directions when it strikes a molecule or particle. There are two 
general techniques for the measurement of physical properties of polymers: Static light 
scattering and dynamic light scattering. In the static light scattering, the intensity of the 
scattered light from the dissolved materials was measured. The amount of light scattered 
is directly proportional to the product of the weight-average molar mass and the solute 
concentration1: LS ~ MW.c (16). To determine the molecular weight of the molecule, the 
analyte concentration is usually measured by refractive index. The differential 
refractometer detects the amount of solute in the column effluent by measuring the 
difference in the RI between the mobile phase and the column effluent containing the 
solute (3). This difference is proportional to the concentration of the solute. The observed 
28 
 
signal (RI), which corresponds to the deviation of the light beam, is proportional to the 
difference in the refractive index of the fluid in the two cells.  
            Based on LS and RI data, three kinds of molecular weight can be calculated using 
discovery® software: Mn, number average; Mw weight average; and Mp (peak molecular 
weight). The width of the distribution, called the polydispersity, is usually determined 
from the ratio of Mw/Mn. The larger the polydispersity index, the broader molecular 
weight. The following are the equations for these molecular weight forms:  
                            
In which, Mi stands for the molecular weight of ith molecules, Ni is the number of ith 
molecules with MW Mi.  
              In our experiment, gel filtration molecular weight markers (Sigma, product 
number: MW-GF-1000) were first applied on SEC column (YMC, Diol-300 column) 
connected with LS detector (PD 2010, Precision Detectors) and RI detector (2414, 
Waters). These markers consist of Carbonic Anhydrase from Bovine Erythrocytes 
(29,000 Da, “CA”), Albumin, Bovine Serum, (66,000 Da, “BSA”), and β-Amylase from 
Sweet Potato (200,000 Da, “Amy”).  
             The instrument setup used for SEC-light scattering experiments consisted of a 
SCL-10 Ai HPLC system (Shimadzu) connected in series with a light scattering detector 
PD2010 (Precision Detectors, MA) and refractomer detector Waters 2414 (Waters). 
Analytical size-exclusion chromatography was carried out at RT using a YMC-Pack 
Diol-300 column (YMC) equilibrated with a mobile phase containing 20 mM Tris-HCl 
(pH 7.5), NaCl 300 mM, and 0.05% (wt) n-dodecyl-β-D-maltoside (“DDM”), if required. 
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100 µl of purified protein sample at indicated concentrations (0.5 µg/µl) was injected into 
the column and eluted at a flow rate of 1.0 ml/min. The column effluent was monitored 
in-line with three detectors that simultaneously monitored UV absorption (280 nm), light 
scattering (90°), and refractive index, respectively. The molecular mass of the proteins 
was calculated from LS and RI data using Discovery® software (Precision Detectors, 
MA). 
 
II.9 Cross-linking of proteins with formaldehyde in vitro 
            Purified AcrA was incubated with E. coli polar lipids (Avanti), as indicated, 
resuspended in 20 mM Hepes (pH 7.0 or 6.0) buffer with increasing concentration of 
NaCl for 20 min. Protein samples were then incubated with formaldehyde (37%, Sigma) 
at indicated final concentrations for 30 min at RT without shaking. The reaction was 
terminated by addition of glycine to final concentration 0.5 M. Protein samples were 
resolved on SDS-PAGE (8%) and visualized by silver staining.  
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Chapter 1 
Limited Proteolysis of AcrA in vitro 
 
1.1 Different cleavage profiles of purified AcrAL-His and AcrAS-His  
            A previous study has shown that AcrAS-His complements the drug-susceptible 
phenotype of ∆acrA cells in vivo (72). This result indicates that the signal peptide of 
OmpA indeed guides the periplasmic translocation of AcrA, and lipid moiety which 
anchors to the inner membrane is not required for the efflux process, at least under over-
expression conditions. However, the effect of lipid modification on the structural features 
of AcrA remains elusive. For example, does this lipid modification on the N-terminal Cys 
residue induce conformational changes in AcrA? 
            To investigate the structural features of proteins, a number of methods or 
techniques can be used. X-ray crystallography is one of the most important approaches to 
probe fine structure of proteins at the molecular level. However, proteins with dynamic 
structure could not be characterized using this technique (10). Another approach, NMR, 
can pinpoint the dynamic conformational transitions in solutions. Nevertheless, it needs 
milli molar concentrations of proteins for measurement, and lacks detailed information 
about partly folded and fluctuating states of proteins due to the resonance broadening as 
well as broad chemical shift dispersions (10). 
            In our studies we used limited proteolysis and fluorescence labeling to study 
dynamic structural changes of AcrA protein. Limited proteolysis is an important 
technique to investigate the tertiary structure of proteins. Three factors are generally 
considered crucial/important during the protease cleavage (22). First, the cleavage sites 
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should be located in the flexible region/domain. Second, cleavage sites exposed to 
medium decrease intermolecular steric hindrance for access to an enzyme’s active site. 
Third, hydrogen bonding, disulfide linkage and van der Waals interactions mediate 
limited proteolysis. Overall, the domains/residues with a high level of flexibility, 
accessibility and extrusion are more susceptible to be degraded by proteases.  
            To characterize structure of AcrA, we used two proteases, proteinase K (“PK”, 
Sigma) and trypsin. PK, a broad specificity protease cleaving at hydrophobic residues, 
was used to digest purified AcrAS-His and AcrAL-His. To purify these two AcrA proteins, 
we transformed plasmids pAcrAHis or pUZ11 into E. coli AG100AX cells, which are 
deficient of acrAB and acrEF multidrug efflux pumps. The AcrAS-His is the fusion 
protein in which OmpA signal peptide substitutes the original signal peptide in AcrA (72). 
Since OmpA signal peptide is cleavable and doesn’t include cysteine residue, AcrAS-His 
is soluble in aqueous medium (72).  
            Because of lac promoter in the plasmids, 0.1 mM of IPTG was used to induce the 
over-expression of AcrA proteins. Figure 1.1 shows the expression profiles of AcrAs. 
These two forms of AcrA were then purified using metal-affinity chromatography as 
described in the Materials and Method section. Purified AcrA variants (1.95 µM) were 
incubated with PK (9.19 nM). The cleavage reactions were terminated at different time 
points by addition of SDS sample buffer. The cleavage profiles of AcrA proteins were 
analyzed by SDS-PAGE (Figure 1.2). 90 min of PK digestion of AcrA variants produced 
several fragments. Compared to the mobility of standard markers, the molecular weights 
of these fragments were determined as 44.0 kDa, 42.0 kDa, 40.6 kDa, 37.6 kDa, 36.0 kDa,  
35.0 kDa,   32.8 kDa,   27.5 kDa,  26.5 kDa,   24.5 kDa,   23.5 kDa.  Among  them,  three  
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Figure 1.1 Expression of AcrA variants. AG100AX carrying pAcrAhis or pUZ11 were 
collected at three hours after IPTG (0.1 mM) induction. Whole cell extracts were resolved 
by 12% SDS-PAGE and stained with CBB.  
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Figure 1.2 Proteinase K cleavage of purified AcrAL-His and AcrAS-His. Proteins (1.95 
µM) were incubated with PK (9.19 nM). The digested AcrA proteins were resolved by 
SDS-PAGE (12%) and stained with silver nitrate. Unique fragments in AcrAL-His sample 
are indicated.  
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fragments (42.0 kDa, 40.6 kDa, and 32.8 kDa) accumulated during the time course. In 
contrast, other fragments (37.6 kDa, 27.5 kDa, 26.5 kDa) rapidly formed in the beginning 
of the digestion (5 min) followed by the further degradation. Although most fragments 
existed in both AcrA samples, we detected some unique bands which were specific to 
these two AcrA variants. The 35.0 kDa and 23.5 kDa fragments were unique in AcrAL-
His sample, whereas 36.0 kDa and 24.5 kDa fragments were exclusively formed in 
AcrAS-His sample. The PK cleavage profile using CBB staining also confirmed this 
observation (data not shown). Different cleavage fragments between AcrAL-His and 
AcrAS-His suggested that lipid modification changes accessibility of residues in AcrA.  
            To further examine the effect of lipid modification on accessibility of AcrA to 
proteases, we used another protease trypsin. Trypsin cleaves the polypeptide chain at the 
C-terminal side of basic residues, arginine and lysine. After trypsin digestion, cleaved 
AcrA fragments were resolved on SDS-PAGE (12%) and idenfied by mass spectrometry.  
          Mass spectrometry is a powerful tool to characterize the peptides formed in limited 
proteolysis (27). There are several basic mass spectrometry techniques in protein 
chemistry. Among them, Matrix-Assisted Laser Desorption/Ionization coupled Time-Of-
Flight (MALDI-TOF) MS takes advantage of the matrix to facilitate the vaporization and 
ionization of biomolecules and thus has become the primary technique in identification of 
peptides and/or proteins in proteomics (27). Here we utilized MALDI-TOF MS to 
measure the m/e values of trypsin-cleaved peptides of AcrA variants, which correspond to 
the molecular weights of these fragments. In particular, AcrAL-His and AcrAS-His were 
treated with trypsin for 60 min as described above and those cleaved fragments were then 
subject to the MS measurements. Meanwhile, intact AcrA variants were used as control.  
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                             A                                                                          B                              
Figure 1.3 SDS-PAGE (12%) analysis of (A) AcrAL-His and (B) AcrAS-His digested with 
trypsin. The cleaved AcrA fragments were then analyzed by MOLDI-TOF MS.  
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Figure 1.4 MALDI-TOF MS spectrum of trypsin cleaved (A) AcrAL-His and (B) AcrAS-
His. After tryptic cleavage, AcrA samples were desalted and concentrated by Ziptip C18, 
followed by MALDI-TOF analysis.  
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Table 1.1 Molecular weights of intact AcrA-His and major tryptic digestion fragments  
peptides MW of AcrAL-His and fragments 
(Dalton) 
MW of AcrAS-His and 
fragments (Dalton) 
 MALDI-TOF 
 
From sequence 
(Calculated) 
MALDI-
TOF 
From sequence 
(Calculated) 
Whole length 41,703 41,622 41,014 40,982 
N-K396 40,435 40,471 39,819 39,830 
Q29-K396 39,597 39,175 39,274 39,175 
T47-K396 37,389 37,367 - 37,367 
Q29-K374 36,558 36,920 - 36,920 
T47-K374 34,909 35,113 - 35,113 
T47-K346 32,025 32,097 31910 32,097 
T47-R315 28,937 28,935 28,967 28,935 
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Figure 1.5 Positions of trypsin cleavage sites on the secondary structure of AcrA. The 
arrow on the left side shows the N-terminal Cys25 which is subject to lipid modification. 
Positions of amino acid residues that form the α-β-barrel, the lipoyl domain and the α-
helical hairpin domains are indicated. AcrA residues cleaved by trypsin are indicated by 
arrowheads.  
            
Figure 1.6 Positions of trypsin cleavage sites on the homology model of AcrA. This 
model was generated using Swiss-Model software 
(http://swissmodel.expasy.org//SWISS-MODEL.html) and the crystal structure of MexA 
as a template (62). Six residues including N-terminal residue T47 (red), and C-terminal 
residues (hotpink) R294/296, R315, K346, K374 in AcrA were labeled in spheres. Note 
that the residues for Q29 and K396 are not visualized in this structural model.  
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             Figure 1.3 (A) shows the tryptic digestion profile of AcrAL-His. Figure 1.4 (A) is 
the corresponding MS spectrum of AcrAL-His. AcrAL-His was cleaved into six bands, 
which were identified by MS on the basis of molecular weights (Da): 40435, 39597, 
37389, 36558, 32025, and 28937. Note that there was an overlap of two peaks (40435 Da 
and 39597 Da) on SDS-PAGE. Figure 1.3 (B) and Figure 1.4 (B) show tryptic digestion 
profile of AcrAS-His and the corresponding MS spectrum. Four trypsin-cleaved 
fragments of AcrAS-His were identified based on molecular weights (Da): 39819, 39274, 
31910 and 28967. The stable 28.9 kDa (T47-R315) fragment was identified in both 
AcrAL-His and AcrAS-His, which is consistent with the previous studies (40, 67). 
            Since trypsin cleaves at the C-terminal side of basic residues, we determined these 
trypsin-cleaved fragments combining the primary sequence of AcrA with the MS data. 
Table 1.1 lists the molecular weights (measured and calculated) of AcrA fragments and 
corresponding AcrA sequence ranges. In agreement with the previous studies (40, 67), 
AcrA was cleaved by trypsin at both termini: two cleavage sites at the N-terminus (Q29 
and T47) and multiple sites at the C-terminus (K396, K374, K346 and R315). To get a 
clear picture of the tryptic cleavage sites on AcrA, these residues are illustrated on the 
secondary structure of AcrA (Figure 1.5) and labeled on the homolog model of AcrA 
(Figure 1.6) in which the crystal structure of MexA is used as a template (62). As shown 
on Figure 1.6, most cleavage sites are located in the MP domain. For example, R315 is 
located on the β-16 strand, K346 is located on the loop between β-18 and β-19 strands, 
and K374 can be found at the end of the MP domain.   
            After the identification of trypsin-cleaved AcrA fragments, we compared the 
tryptic digestion of AcrA variants in the time course (Figure 1.7). It showed that the 
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cleavage profile of AcrAS-His was different from that of AcrAL-His. First, the stable 28.9 
kDa core (T47-R315) formed slower in AcrAL-His than in AcrAS-His. This can be 
interpreted that this site (R315) is protected by lipid moiety. Second, the 32.1 kDa 
fragment (T47-K346) in AcrAL-His rapidly formed and accumulated. However, this 
fragment in AcrAS-His formed slower, and the amount of this fragment decreased during 
the time course. Both observations are consistent with the principle of mass conservation. 
Compared to the tryptic digestion of AcrAS-His, slower formation of the 28.9 kDa 
fragment (T47-R315) is coupled with the faster accumulation of the 32.1 kDa fragment 
(T47-K346) in the tryptic digestion of AcrAL-His, therefore supporting the steric 
hindrance of lipid modification on residue R315 during the tryptic cleavage of AcrA 
variants.   
            Since oxidative phosphorylation and electron transport chain on the inner 
membrane of E. coli results in the accumulation of protons in the periplasm, the  pH in 
the periplasm is about 6.0 (36). To characterize the effect of pH changes on the structural 
features of AcrA, we carried out the tryptic digestion of AcrA at pH 6.0 (Figure 1.7, B). 
Our result showed that the profiles under two pH conditions (pH 6.0 and pH 7.0) are very 
similar, suggesting that the pH change from 7.0 to 6.0 does not result in significant 
structural changes in AcrA. This result is also consistent with a previous study in which 
acidic pH 5.0 rather than pH 6.0 induces the conformational changes in AcrA (25).  
            Taken together, these results demonstrated that trypsin and PK cleave AcrAS-His 
and AcrAL-His differently. In the tryptic digestion, faster accumulation of the 32.1 kDa 
fragment (T47-K346) and slower formation of the 28.9 kDa fragment (T47-R315) of 
AcrAL-His can be explained as a protective effect of lipid modification on residue R315.  
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         A  
                   
 
        B 
         
Figure 1.7 Time course of tryptic digestion of AcrAL-His and AcrAS-His at (A) pH 7.0 
and (B) pH 6.0. Purified AcrA variants (1.95 µM) were digested with trypsin (0.10 µM). 
Tryptic fragments were resolved by SDS-PAGE (12 %) and stained with silver nitrate.  
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1.2 Effect of lipids on the accessibility of AcrA to trypsin 
            Membrane protein reconstitution into liposomes has been widely used to 
characterize the functional and structural features of membrane proteins (54). To evaluate 
the effect of AcrB on structure of AcrA, we reconstituted AcrAL-His alone or together 
with AcrB-His into proteoliposomes. In this experiment, E. coli polar lipid extract 
(Avanti Polar Lipids, 100600) was emulsified in 20 mM Hepes (pH 7.0) buffer including 
0.45% (wt) Triton X-100 (TX) and 5 mM DTT, and proteins were then added. After 
incubation of AcrAL-His or AcrAL-His together with AcrB-His in lipid samples for thirty 
minutes at room temperature, TX was removed by adsorption to Bio-beads (Bio-Rad). 
Proteins (AcrAL-His and AcrB-His) incorporated into proteoliposomes were quantified 
by SDS-PAGE (12%) stained with CBB (Figure 1.8). In this experiment, BSA was used 
as control.  
            To assess whether the interaction between AcrAL-His and AcrB-His causes the 
structural changes in AcrA, the reconstituted proteoliposomes were resuspended in 20 
mM Hepes (pH 7.0) and 100 mM NaCl, followed by the trypsin treatment. Cleavage 
profiles of AcrAL-His alone and AcrAL-His plus AcrB-His in the proteoliposomes were 
very similar (Figure 1.9). Although these two proteins can form a complex in vivo (66, 67, 
74), our result suggests that AcrA does not interact with AcrB efficiently in vitro, or that 
the AcrA-AcrB interaction does not result in the apparent conformational changes in 
AcrA or provide steric hindrance during the trypsin cleavage of AcrA.  
            When we examined the tryptic cleavage of AcrAL-His in the presence and absence 
of lipids, surprisingly, we found that proteolytic profile of AcrA L-His without lipids was 
different  from that  in the presence of lipids. First, not all AcrAL-His in  proteoliposomes  
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Figure 1.8 Quantification of AcrAL-His and AcrB-His reconstituted into proteoliposomes. 
After reconstitution into proteoliposomes, proteins were resolved by SDS-PAGE (12%) 
and stained with CBB. AcrAL-His concentrations in the AcrAL-His (PL) and AcrAL-His 
with AcrB-His (PL) are 0.173 mg/ml and 0.167 mg/ml, respectively. The AcrB-His 
concentration in the proteoliposomes is 0.085 mg/ml.  
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 B 
   
Figure 1.9 Tryptic digestion of AcrAL-His-containing proteoliposome at (A) pH 7.0 and 
(B) pH 6.0. Purified AcrAL-His was reconstituted into proteoliposomes alone or together 
with purified AcrB-His. Proteoliposomes were treated with trypsin, in which the 
concentrations of AcrAL-His and trypsin are 0.73 µM, and 0.11 µM, respectively. AcrAL-
His in the absence of lipids was used as control (left). Tryptic fragments were resolved by 
12 % SDS-PAGE and analyzed by immuno-blotting with anti-AcrA antibodies.  
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was cleaved during the time course. Second, we detected the 28.9 kDa fragment (T47-
R315) in ten minutes in the presence of lipids and in 30 min in the absence of lipids. This 
result implied that the cleavage sites for this fragment are more exposed to external 
medium when AcrAL-His is incorporated into liposomes. In addition, in the absence of 
lipids five fragments at 37.4 kDa (T47-K396), 36.9 kDa (Q29-K374), 32.1 kDa (T47-
K346), 28.9 kDa (T47-R315) and 26.5 kDa (T47-R296) accumulated, whereas in the 
presence of lipids the amounts of these fragments reduced during the time course. This 
observation suggests that these AcrA fragments are more labile to trypsin once AcrAL-
His is reconstituted into liposomes. 
            Since the pH in the periplasm is about 6.0 (36), we next examined the pH effect 
(from pH 7.0 to 6.0) on AcrA digestion in the presence of lipids. Tryptic digestion was 
carried out as described above except at pH 6.0 (Figure 1.9 B). The presence of lipids and 
digestion at pH 6.0 did not change the tryptic cleavage profile of purified AcrAL-His. 
This result suggested that there are no significant structural changes in AcrAL-His due to 
this pH transition. 
            In the above experiments, the AcrAL-His sample without E. coli polar lipids was 
treated with trypsin in the presence of 3.2 mM TX. To assess the effect of TX on the 
limited tryptic proteolysis of AcrAL-His reconstituted into proteoliposomes, a similar 
experiment was performed in the presence of 3.2 mM TX. We found that 3.2 mM TX 
does not significantly affect the tryptic digestion of AcrAL-His when present in the 
detergent-lipid mixture (data not shown).  
            During the above described reconstitution experiments, the lipid moiety of 
AcrAL-His was expected to interact with E. coli polar lipids emulsified in detergent TX 
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buffer. Therefore AcrA could associate with either the inner or the outer leaflet of lipid 
bilayer upon the removal of TX. In this case, AcrAL-His bound to outer leaflet is 
accessible to trypsin, whereas inner leaflet-bound AcrAL-His is inaccessible. To avoid the 
burial of AcrA inside the liposomes, lipid(20 mM)-TX(3.2 mM) mixed vesicles were 
preformed before the addition of the purified AcrAL-His without sonication. This direct 
incubation made all AcrAL-His inserted into the outer leaflet of liposomes and exposed to 
trypsin. Similar to the reconstituted proteoliposomes, Figure 1.10 A shows that some 
amount, approximately 50%, of intact AcrAL-His was not cleaved in 90 minutes, whereas 
the rest was cut in five minutes. When this incubation was extended to overnight, the 
amount of intact AcrAL-His did not significantly decreased (data not shown). The same 
results were obtained in the overnight incubation of whole cells or membrane fractions 
with trypsin (data not shown). Trypsin-resistance of AcrA in the presence of lipid bilayers 
indicated that AcrAL-His exist in, at least, two states: one is trypsin-vulnerable, and the 
other is trypsin-resistant. In addition, we detected the trace amount of the 32.1 kDa 
fragment (T47-K346) in the presence of lipids, compared to significant accumulation of 
this fragment in the absence of lipids (Figure 1.10 A). Besides, the 28.9 kDa fragment 
(T47-R315) in the presence of lipids accumulated faster than without lipids. This result 
illustrated the higher susceptibility of the cleavage site R315 to trypsin in the presence of 
lipids. 
            However, when AcrAS-His was incubated with E. coli polar lipids followed by the 
tryptic digestion, the cleavage profile was the same as without lipids (Figure 1.10 B). 
This result implied that E. coli polar lipids do not induce structural changes in AcrAS-His.  
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 B 
                   
Figure 1.10 Tryptic digestion of (A) AcrAL-His and (B) AcrAS-His in the presence of 
detergent-lipid mixed vesicles. The concentration of lipids and TX are 20 mM and 3.2 
mM, respectively. Purified AcrA variants (1.95 µM) were incubated with lipids (25.6 
mM), followed by digestion with trypsin (0.10 µM). AcrA variants without lipids were 
used as control. Tryptic fragments were resolved by 12 % SDS-PAGE and analyzed by 
silver staining.  
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Figure 1.11 Effect of lipids on tryptic digestion of AcrAL-His. AcrA was pre-incubated 
with increasing concentrations of lipids in the presence of 3.2 mM TX. After 15 min 
incubation with trypsin, reactions were terminated by boiling in SDS-sample buffer and 
analyzed by SDS-PAGE (12%). 
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            Previous studies showed that lipids can exist as micelles and/or vesicles under 
different lipid:TX molar ratios (34, 65). Specifically, lipids dominantly exist in micelles 
when the molar ratio of lipids and TX is about 0.16, but lipid bilayers are formed as this 
ratio increases. Most lipids form vesicles when the ratio is increased to 1. In above 
experiments a large amount of E. coli polar lipids were incubated with AcrA variants. The 
molar ratio of lipids and TX was 6.4. In this case, lipids existed as vesicles even in the 
presence of 3.2 mM TX.  
            To investigate how accessibility of AcrA to trypsin changes with lipid phases, we 
incubated purified AcrAL-His with different concentrations of E. coli polar lipid samples. 
The concentration of TX was set constant at 3.2 mM. Figure 1.11 shows the cleavage 
profile after 15 minutes incubation with trypsin. At the lowest lipid:TX ratio, the cleavage 
profile of AcrAL-His was similar to that in the absence of lipids. In contrast, when 
lipid:TX molar ratio was increased to 1, or the lipid:AcrA ratio rose to about 30 (wt/wt), 
the amount of the 32.1 kDa fragment (T47-K346) decreased, whereas the 28.9 kDa 
fragment (T47-R315) accumulated. Moreover, when lipid:TX molar ratio was increased 
to 3.2 or the lipid:AcrA ratio was above 100 (wt/wt), some amount of intact AcrAL-His 
became resistant to trypsin. Therefore our result demonstrated that the presence of lipid 
bilayers (lipid:TX molar ratio is above 1) is required to change proteolytic profiles of 
AcrA, especially in the formation of the 28.9 kDa fragment (T47-R315). This result 
suggested that interactions between AcrAL-His and lipid bilayers increase the 
susceptibility of residue R315 to trypsin. On the other hand, decreased amount of the 32.1 
kDa fragment (T47-K346) in the presence of lipid bilayers indicates that this fragment 
was rapidly cleaved into the stable 28.9 kDa core (T47-R315) or the accessibility of the 
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cleavage site K346 reduced. Besides, some intact AcrAL-His is trypsin resistant when the 
lipid:TX molar ratio was above 3.2, suggesting that lipid vesicles protect AcrAL-His from 
digestion.  
            Taken together, these results demonstrated that AcrAL-His reconstituted into 
proteoliposomes or in the presence of detergent-lipid mixed vesicles was cleaved 
differently from that in the absence of lipids. In particular, the cleavage site R315 of the 
28.9 kDa fragment (T47-R315) is more exposed to medium in the presence of 
vesicles/proteoliposomes. In addition, no significant accumulation of the 32.1 kDa 
fragment (T47-K346) in the presence of lipid bilayers suggests that this fragment is 
rapidly digested to form the stable 28.9 kDa core (T47-R315) or is formed slowly due to 
the reduced accessibility of the cleavage site K346. Both residues (R315 and K346) are 
located in the MP domain of AcrA (Figure 1.6), which is predicted to interact with the 
cytoplasmic membrane. Different susceptibility of the cleavage sites of AcrA to trypsin 
can be interpreted as the protection by lipid modification, or structural changes in AcrA. 
However, we did not observe the effect of E. coli polar lipids on the tryptic digestion of 
AcrAS-His, thus lipid vesicles do not likely induce the structural variations in AcrAS-His. 
In addition, when we compared proteolytic profiles of two AcrA variants in the presence 
of detergent-lipid vesicles, we detected the faster accumulation of the 28.9 kDa fragment 
(T47-R315) in AcrAL-His than that of AcrAS-His. This observation indicated that, 
compared to AcrAS-His, the cleavage site R315 in AcrAL-His is more exposed to aqueous 
medium when AcrA is associated with the lipid bilayer, given that the lipid modification 
and lipid bilayers do not interfere with the trypsin cleavage of AcrAL-His. Moreover, we 
did not detect a significant pH effect on the structural changes under all tested conditions.  
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1.3 Different accessibility of AcrA-Cys mutants to thiol-reactive probes in vitro and 
in vivo 
            To compare the conformations of AcrA in vivo and in vitro, we used an approach 
based on fluorescence labeling (60, 69). In our study, fluorescein-5-maleimide (F5M) was 
used to covalently attach the fluorophore fluoresceine to a cysteine residue introduced by 
site-directed mutagenesis into AcrA. The reactivity of F5M was used to probe the 
accessibility of the Cys residue, thereby characterizing the conformational features in 
AcrA.  
            A previous study has shown that AcrAS mutants containing single Ala -> Cys 
substitution can complement the function as a wild type (25). These AcrAS-Cys mutants 
include A30C, A39C, A62C, A103C, A146C, A172C, A204C, A242C, A295C, A339C, 
and A390C. These positions were placed in the AcrA structure which was modeled based 
on the crystal structure of MexA (62). As shown on Figure 1.12, A39C and A339C are 
located in the MP domain, A62C, A242C and A295C are positioned in the α-β barrel 
domain, A103C, A146C and A172C are located in the α-helical hairpin domain, and 
A204C are found in the lipoyl domain.  
             To conduct the fluorescence labeling of AcrAS-Cys in vivo, plasmids over-
expressing AcrAS-Cys mutants and WT (AcrAS without Cys mutation) were transformed 
into AG100AX. After induction with IPTG, AcrAS-Cys mutants as well as WT were 
treated with F5M. Labeled cells were lysed by sonication. Proteins were purified by the 
metal affinity chromatography and analyzed by fluorescence scanning followed by CBB 
staining of SDS-PAGE. Image Quant® software was then used to quantify the 
fluorescence as well as the amounts of proteins.  
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            In parallel experiments, AcrAS-Cys mutants were labeled in vitro. For this 
purpose, AcrAS-Cys proteins were purified first, and then treated with F5M.  
            Figure 1.13 demonstrates the AcrAS-Cys-labeling profiles in vivo and in vitro. 
Figure 1.14 shows the fluorescence intensities of non-lipidated AcrAS-Cys mutants in 
vivo and in vitro. To clarify the labeling result, we organized the labeling profiles in vivo 
and in vitro in Table 1.2.  
             As seen in the Table 1.2, Cys39, Cys62, Cys103, and Cys242 are more accessible 
to be labeled with F5M in vivo than in vitro. Furthermore, Cys62 and Cys242 were 
partially labeled inside the cell but were not labeled in the purified proteins. These results 
suggested that these Cys residues might be located in the flexible domain of AcrA and 
conformational flexibility results in the accessibility heterogeneity. For example, half of 
these residues (Cys 62, Cys242) are accessible and the remaining 50% of the residues are 
inaccessible. 
            In addition, we found that standard derivation errors in our data are too large. 
Some errors are close to or even larger than the values themselves, especially in Cys 39 
(in vitro), 62 (in vivo), 103 (in vivo and in vitro), and 242 (in vivo and in vitro). These 
significant standard derivation errors indicated that our data are not reproducible. 
Although our observations suggested the different accessibility of F5M to Cys in AcrA 
mutants, further studies are required to confirm this result.  
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Figure 1.12 Positions of Cys substitutions in the homolog model of AcrA. This model 
was generated using Swiss-Model software (http://swissmodel.expasy.org//SWISS-
MODEL.html) and the crystal structure of MexA as a template (62). Nine residues A39C, 
A62C, A103C, A146 C, A172C, A204C, A242C, A295C and A339C are labeled in red 
spheres. Note that residues for both A30C and A390C are not visualized in this structural 
model.  
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Figure 1.13 AcrAS-Cys labeling in vivo and in vitro. F5M panels are fluorescence profiles 
of AcrAS-Cys mutants, and CBB panels are corresponding protein profiles. (A) In vivo 
labeling of AcrAS-Cys mutants and WT (AcrA without Cys mutation). Whole cells were 
incubated with 100 µM F5M in PBS for 30 min. Labeled AcrAS-Cys variants and WT 
were purified and analyzed by SDS-PAGE (12%). Fluorescence was detected using 
Storm 840 Imager (Molecular Dynamics). The excitation wavelength and the emission 
wavelength were set at 450 nm and 520 nm, respectively. (B) In vitro labeling of AcrAS-
Cys. AcrAS-Cys mutants and WT were purified and then labeled with 20 µM F5M. 
Fluorescence measurement was carried out as in (A).  
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Figure 1.14 Quantification of fluorescence labeling of AcrAS-Cys in vivo and in vitro. 
Fluorescence intensities and protein amounts of AcrAS-Cys mutants and WT were 
quantified using Image Quant® program. The fluorescence intensity was normalized onto 
protein amounts. Error bars are standard deviations (n = 3) 
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Table 1.2 Fluoresceine-5-maleimide labeling of AcrAS-Cys in vivo and in vitro. 
“++” stands for accessible, “+” for partial accessible, “-“ for inaccessible 
Position of Cys Domain Labeling in vivo Labeling in vitro 
30 -- ++ ++ 
39 MP ++ + 
62 α, β-barrel + - 
103 α-helical hairpin ++ + 
146 α-helical hairpin - - 
172 α-helical hairpin ++ ++ 
204 Lipoyl - - 
242 α, β-barrel + - 
295 α, β-barrel - - 
339 MP - - 
390 -- ++ ++ 
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Chapter 2  
Effect of AcrB and TolC on the Proteolytic Accessibility of AcrA 
 
            To understand the function mechanism of AcrA inside the cell, we characterized 
the structure of AcrA, especially the MP domain, in vivo. Here we used in vivo limited 
proteolysis to digest AcrA inside E. coli strains with different genetic backgrounds. Two 
strains were used: AG100AX in which both acrA-acrB and acrE-acrF multidrug efflux 
pumps are deleted from the chromosome, and ECM2112 lacking acrA, acrB and tolC. 
Using the identified AcrA fragments as a map, we characterized the the structure of over-
produced AcrAL-His in vivo, given that the over-produced AcrAL-His functions well 
during the multi-drug efflux (38). For this purpose, we transformed the plasmid over-
expressing AcrAL-His into these two strains. The proteolytic profile of AcrA in vivo was 
analyzed by using anti-AcrA antibodies. Since TolC is expressed in AG100AX but not in 
ECM 2112 strain, comparison of cleavage profiles of AcrA from these two strains should 
reflect the effect of TolC on the accessibility of the over-expressed AcrA to trypsin. It 
should be noted that AcrB was not expressed in both strains.  
            Previous studies demonstrated that different complexes AcrA-AcrB, AcrA-TolC 
and AcrA-AcrB-TolC were formed inside the cells (32, 62, 66, 67, 73). In our 
experiments, in vivo limited proteolysis was used to characterize the conformations of 
AcrA in different complexes (AcrA-AcrB, AcrA-TolC, and AcrA-AcrB-TolC), which 
provides insight into the functional assembly of the multidrug efflux complex AcrAB-
TolC. In particular, three stains were used: AG100, wild type (WT) producing the intact 
AcrAB-TolC complex; ZK796, delta TolC (∆TolC) mutant expressing only AcrAB; and 
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AG102MB, delta AcrB (∆AcrB) mutant producing AcrA and TolC. To make AcrA 
accessible to trypsin in the periplasm, we applied osmotic shock (20% sucrose Tris-EDTA 
buffer). This approach was previously shown to permeabilize the OM to trypsin (44).    
 
2.1 Proteolytic profile of the overexpressed AcrA-His in cells is similar to that of 
purified AcrAL-His 
            To reveal the function mechanism of AcrA in vivo, we used the limited proteolysis 
to characterize the conformations of the MP domain in the over-produced AcrA inside the 
cells. For this purpose, plasmid pAcrAhis over-expressing AcrAL-His was transformed 
into E. coli cells (AG100AX and ECM2112). Figure 2.1 (B) shows the trypsin cleavage 
profile of AcrA in vivo visualized by immunoblotting. Even without trypsin, some over-
produced AcrAL-His was degraded by endogenous periplasmic proteases. To identify the 
tryptic fragments of AcrA, we titrated whole cells with increasing amounts of trypsin. 
Several trypsin-specific bands of AcrAL-His overexpressed in AG100AX were identified 
by comparison to the in vitro tryptic digestion (Figure 2.1 A): 37.4 kDa (T47-K396), 36.9 
kDa (Q29-K374), 32.1 kDa (T47-K346), 28.9 kDa (T47-R315), and 26.5 kDa (T47-
R294/R296). All these fragments were detected when AcrA was treated with trypsin in 
vitro. Thus, in vivo cleavage profile of AcrAL-His was similar to that of the purified 
AcrAL-His. Although the 26.5 kDa fragment (T47-R294/R296) was poorly detected by 
silver staining (Figure 1.7), this fragment can be clearly detected by immunoblotting in 
the AcrAL-His digestion in vivo.   
            AcrAL-His over-expressed in ECM2112 (∆AcrAB-TolC) displayed the proteolytic 
profile similar to that  in  AG100AX cell (data not shown),  suggesting that TolC does not  
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Figure 2.1 Tryptic digestion of overexpressed AcrAL-His in vivo and in vitro. (A) Tryptic 
digestion of AcrAL-His in vitro. Purified AcrAL-His (1.95 µM) was treated with trypsin 
(0.10 µM). Tryptic fragments were resolved by SDS-PAGE (12%) and analyzed by silver 
staining. (B) Tryptic digestion of overproduced AcrAL-His in vivo. AcrAL-His was over-
produced in E. coli AG100AX cells carrying pAcrAHis and pAcrAHisAcrB plasmids. After 
treatment with increasing concentrations of trypsin for 60 min at 37ºC, the whole cell 
proteins were resolved by SDS-PAGE (12%) and analyzed by immunoblotting with anti-
AcrA antibody. O.D. - the optical density as determined by absorbance at 600 nm. 
 
 
 
 
 
60 
 
affect the tryptic cleavage of the over-produced AcrAL-His inside the cell. We therefore 
concluded that over-expressed AcrAL-His in vivo adopts the conformation similar to that 
of the purified AcrAL-His.  
            We did not detect any changes in the tryptic cleavage of the purified AcrAL-His in 
the presence of AcrB-His (Figure 1.9). We next examined whether AcrB-His inside the 
cell affects digestion of the over-produced AcrAL-His. For this purpose, we used 
pAcrAhisAcrB plasmid which over-expressed both AcrAL-His and AcrB-His under the 
native acrA promoter. This plasmid was transformed into AG100AX cells and the similar 
trypsin titration was conducted as described as above. As shown on Figure 2.1 (B), the 
same cleavage fragments of AcrAL-His were obtained in the presence of AcrB-His, 
indicating that over-expression of AcrB-His together with AcrAL-His did not significantly 
affect the tryptic cleavage profile of AcrAL-His. Nevertheless, we found that, when 
treated with the high concentration of trypsin (10 µg/O.D.), the amount of the 26.5 kDa 
fragment (T47-R294/R296) was higher in cells over-producing AcrAL-His and AcrB-His 
than in cells over-producing AcrAL-His alone. This result suggested that AcrB-His 
interaction with AcrAL-His inside the cells protects this 26.5 kDa fragment (T47-
R294/R296) from further cleavage.  
            Taken together, these results showed that the overall structure of over-produced 
AcrAL-His inside the cells is similar to that of purified AcrAL-His and other components 
(AcrB and TolC) don’t significantly affect the conformation of AcrAL-His in vivo.  
 
2.2 AcrB-His and TolC-His affect the trypsin accessibility to AcrAL-His in vivo 
            Previous studies showed that AcrA-AcrB-TolC form a stable complex spanning 
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the two membranes in E. coli (66, 67). More recent studies further demonstrated that the 
lipoyl domain, β-barrel domain and MP domain in AcrA interact with the periplasmic 
domain of AcrB, whereas the N-terminal helix of AcrA packs against TolC helical coils 
(35, 62). Although the proposed docking model utilized computational energy 
minimization and site-specific in vivo cross-linking to optimize the AcrA-AcrB-TolC 
assembly, experimental evidence is still needed to further validate the putative 
conformational changes in AcrA during the complex assembly. For example, does 
interaction with AcrB or TolC induce different conformations of AcrA? How do the 
putative structural changes in AcrA as well as the protein-protein interactions (AcrA-
AcrB or AcrA-TolC) coordinate during assembly of the functional tripartite complex 
(AcrA-AcrB-TolC)? 
            Here we used trypsin digestion of AcrA expressed in three strains AG100 (WT), 
AG102MB (∆AcrB), and ZK796 (∆TolC) to investigate the effect of AcrB and TolC on 
AcrA. First, the three strains were treated with increasing amounts of trypsin for five 
minutes and one hour (Figure 2.2). Although chromosomally produced AcrA was also 
cleaved by endogenous proteases in the periplasm, the amounts of cleaved fragments 
were much less than those of AcrA over-expressed from plasmids (Figure 2.1, B).  
            The comparison of the tryptic digestion profiles showed that similar AcrA 
fragments were produced in AG102MB (∆AcrB) and ZK796 (∆TolC) cells. When the 
trypsin concentration was increased, the amount of the 37.4 kDa (T47-K396), 36.9 kDa 
(Q29-K374), and 26.5 kDa (T47-R294/R296) decreased. On the other hand, some 
amount of the 28.9 kDa fragment (T47-R315) was detected. The profile of AG100 (WT) 
was different from those of AG102MB (∆AcrB) and ZK796 (∆TolC). Particularly, rapidly  
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A 
                              
B 
                              
Figure 2.2 Tryptic digestion of chromosomally produced AcrA in E. coli cells with 
different genetic backgrounds. (A) WT, ∆TolC and ∆AcrB cells were treated with trypsin 
at indicated concentrations for 5 min. (B) WT, ∆TolC and ∆AcrB cells were treated with 
trypsin at indicated concentrations for 60 min. E.coli AG100 (WT), ZK796 (∆TolC) and 
AG102MB (∆AcrB) were grown to mid-exponential phase (A600 ~ 1.0). Cells were 
collected and treated with increasing concentrations of trypsin at 37ºC. Total proteins 
were resolved by 12% SDS-PAGE and AcrA fragments were visualized by anti-AcrA 
western blotting.  
63 
 
 
 
 
  
 
Figure 2.3 Time course of tryptic digestion of AcrA in E. coli strains with different 
genetic backgrounds. E.coli AG100 (WT), ZK796 (∆TolC) and AG102MB (∆AcrB) 
were grown to mid-exponential phase (A600~ 1.0). Cells were collected and digested with 
trypsin (1.0 µg/O.D.). Aliquots were taken at 0, 5, 10, 30, 60, and 120 min and reactions 
were terminated by addition of SDS-sample buffer. Total proteins were resolved by 12% 
SDS-PAGE and AcrA fragments were visualized by anti-AcrA western blotting. 
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accumulated 37.4 kDa (T47-K396)  and  36.9 kDa (Q29-K374)  fragments were further    
cleaved in AG102MB (∆AcrB) and ZK796 (∆TolC) cells, whereas these fragments were 
resistant to further digestion in AG100 (WT) strain. Besides, the small amount of 28.9 
kDa fragment (T47-R315) can be visualized in AG102MB (∆AcrB) and ZK796 (∆TolC) 
strains, compared to no evident 28.9 kDa band (T47-R315) in AG100 cells. Furthermore, 
at the high concentration of trypsin or after treatment extended to one hour, the 26.5 kDa 
fragment (T47-R296/R294) accumulated in AG100 (WT) strain. In contrast, this 
fragment was further cleaved in the other two strains (∆AcrB and ∆TolC).  
            To further confirm that AcrA cleavage depends on genetic backgrounds of cells, 
we conducted the time course of trypsin proteolysis in these three strains. E coli cells 
were incubated with trypsin at concentration 1.0 µg/O.D and proteolysis was analyzed at 
5, 10, 30, 60, and 120 minutes after addition of trypsin. Anti-AcrA immunoblotting 
showed the 40.4 kDa (N-K396), 37.6 kDa (T47-K396), 36.9 kDa (Q29-K374), 32.1 kDa 
(T47-K346), 28.9 kDa (T47-R315), and 26.5 kDa (T47-R294/R296) fragments (Figure 
2.3). In agreement with the trypsin titration result, the cleavage profiles of AG102MB 
(∆AcrB) and ZK796 (∆TolC) were similar. On the other hand, the 37.4 kDa (T47-K396), 
36.9 kDa (Q29-K374), and 26.5 kDa (T47-R294/R296) fragments were further digested 
in both AG102MB (∆AcrB) and ZK796 (∆TolC) strains. However, these three fragments 
were accumulated in AG100 (WT) strain during the time course. This result suggested 
that lack of any components, AcrB or TolC, resulted in the changes of AcrA accessibility 
to trypsin.  
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       A 
                      
       B 
                     
Figure 2.4 Effect of (A) AcrB and (B) TolC on the in vivo tryptic digestion of AcrA. 
ZK796 (∆TolC) and AG102MB (∆AcrB) cells were transformed with pTolChis and 
pAcrBhis plasmids producing TolC and AcrB, respectively or with pUC18 vector alone. 
Cells were collected and treated with increasing concentrations of trypsin for 60 min at 
37ºC. Total proteins were resolved by 12% SDS-PAGE and AcrA fragments were 
visualized by anti-AcrA immunoblotting.  
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2.3 AcrB-His and TolC-His protect the C-terminal domain of AcrAL-His in vivo  
            To confirm that changes in proteolytic profiles of AcrA are caused by the lack of 
AcrB or TolC, we transformed plasmids expressing AcrB-His or TolC-His into 
AG102MB (∆AcrB) or ZK796 (∆TolC) strains respectively, and then investigated AcrA 
accessibility to trypsin (Figure 2.4). When the plasmid expressing AcrB-His was 
introduced in AG102MB (∆AcrB) strain, the trypsin cleavage profile of AcrA became 
similar to that of AG100 (WT) strain: rapid digestion of 37.4 kDa (T47-K396)/36.9 kDa 
(Q29-K374) fragments and accumulation of the 26.5 kDa fragment (T47-R294/R296). 
When the plasmid borne TolC was produced in ZK796 strain (∆TolC), the trypsin 
cleavage profile at 60 min was very similar to that of AG100 (WT) strain. This 
experiment demonstrated that, once AcrB or TolC is expressed in ∆AcrB cells or ∆TolC 
cells, respectively, to form the functional tripartite complex, AcrA accessibility to trypsin 
changed and the C-terminal domain of AcrA was protected from further digestion.  
 
2.4 Trypsin digestion of AcrA in the presence of AcrB or TolC in vitro 
            The experiments described above demonstrated that the functional tripartite 
complex assembly protects the C-terminal domain of AcrA. We next performed trypsin 
digestion of the purified AcrA in the presence and absence of AcrB and/or TolC. The goal 
of these experiments was to establish whether AcrAB-TolC complex is assembled in vitro. 
AcrB-His and TolC-His were purified using metal-affinity chromatography as described 
in Methods. Figure 2.5 shows the SDS-PAGE analysis of the purified AcrB and TolC 
proteins. For limited trypsin proteolysis, purified AcrAL-His was incubated with AcrB-
His or TolC-His in the presence of E. coli polar lipid vesicles which were resuspended in 
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20 mM Hepes (pH7.0) buffer containing 3.2 mM TX and 100 mM NaCl. The cleavage  
fragments were resolved by SDS-PAGE and visualized by silver staining. 
             Figure 2.6 (A) shows the tryptic cleavage profiles of AcrA alone, AcrB alone, and 
AcrA-AcrB mixture. AcrB was rapidly degraded into several fragments with apparent 
molecular weights at 70 kDa, 55 kDa, 53 kDa, 52 kDa, and 40.5 kDa as estimated by 
comparison to the standard markers. Moreover, the 70 kDa fragment was further cleaved 
during the time course. When AcrA and AcrB were mixed together, AcrB was cleaved 
into the same fragments as AcrB alone. Similarly, the tryptic cleavage profile of AcrA 
was not affected by the presence of AcrB. This result suggested that incubation with AcrB 
in vitro does not induce conformational changes in AcrA or protection of cleavage sites in 
AcrA. This result is also consistent with that of proteoliposome cleavage (Figure 1.9).  
            Figure 2.6 (B) shows the tryptic digestion profiles of AcrA alone, TolC alone, and 
AcrA-TolC mixture. TolC was digested in 5 min into three major fragments with apparent 
MW at 50 kDa, 27 kDa, and 25 kDa as estimated by comparison to the standard markers. 
When AcrA and TolC were mixed together, TolC was digested into the same fragments as 
TolC alone. However, incubation with TolC resulted in the slower formation of the stable 
AcrA core (28.9 kDa). This slower accumulation could be due to protection of R315 of 
AcrA by interactions with TolC.  
            Previous studies have shown that AcrB and TolC bind to different domains of 
AcrA (35, 62). Here we demonstrated that AcrB and TolC affect the accessibility of AcrA 
to trypsin in vivo. Association with either AcrB or TolC results in the similar cleavage 
profile of AcrA in vivo. Interestingly, the accessibility of AcrA in the functional tripartite 
complex is different  from  that  in either AcrA-AcrB  or AcrA-TolC  bipartite complexes. 
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Figure 2.5 SDS-PAGE (12%) analysis of purified AcrB and TolC. Proteins were 
visualized by silver staining. 
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Figure 2.6 Effect of AcrB (A) and TolC (B) on the in vitro tryptic digestion of purified 
AcrA. Purified AcrA was incubated with purified AcrB or TolC in the presence of E. coli 
polar lipid vesicles, followed by trypsin digestion. Aliquots were taken at 0, 5, 10, 30, 60, 
and 90 min and reactions were terminated by SDS-sample buffer. The tryptic fragments 
were resolved by 12% SDS-PAGE and visualized by silver nitrate staining.
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This specific AcrA profile in the functional tripartite complex was confirmed by the 
complementation   experiment   in which   AcrB   or   TolC   was   introduced   into    the 
corresponding ∆AcrB or ∆TolC strains. The simplest interpretation for this result is that 
new interfaces which are formed during the assembly of the three component complex 
protect the C-terminal domain of AcrA (315-397 a.a). However, we can not exclude the 
possibility that AcrA undergoes conformational changes during the functional tripartite 
complex assembly. In addition, the effect of AcrB and TolC on the tryptic cleavage of 
AcrA in vitro was also investigated. We didn’t detect the changes of AcrA cleavage due to 
AcrB. In contrast, the slower accumulation of the 28.9 kDa fragment (T47-R315) during 
the time course possibly results from the protection of R315 by AcrA-TolC interactions.  
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Chapter 3  
Oligomerization of AcrA 
 
3.1 AcrAS-His forms oligomers in the presence of E. coli polar lipids  
            Oligomerization of MFPs including AcrA is a controversial topic. Even in the 
research of non-lipidated soluble AcrA, different oligomerization results were reported. A 
hydrodynamic study showed that AcrAS-His predominantly exists as a monomer in 
solution (72). In contrast, an electron microscopy study demonstrated a dimer 
configuration of AcrA crystallized on lipid layers (2). Besides, a dimer of dimers was 
found in the X-ray crystal structure of AcrA core (53-299 a.a) (42). Interestingly, 
oligomers including trimers and dimers were detected in DSG cross-linking in vivo (74). 
To further address this “conflicting” oligomerization status of AcrAS-His in vivo and in 
vitro and elucidate the assembly mechanism of the homo-oligomers, we used 
formaldehyde (FA) to cross-link oligomers of AcrA in vitro.  
            Formaldehyde (formula H2CO) is one of the smallest and shortest cross-linkers. 
The structural study showed that the spacer arm of formaldehyde is about 2.3-2.7 Å (61). 
As shown in Figure 3.1, formaldehyde can bind a nitrogen atom or other atoms if two 
atoms are close within the spacer arm of formaldehyde, forming a cross-linked methylene 
bridge (-CH2-). Thus, formaldehyde has been widely used in fixation and/or cross-linking 
to capture the fine structural details in light/electron microscopy studies and mass 
spectrometry experiments (61).  
             To investigate oligomerization of AcrA, we incubated AcrAS-His with increasing 
concentrations of formaldehyde (Sigma) in 20 mM Hepes-KOH (pH 7.0) and 100 mM    
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Figure 3.1 Mechanism of formaldehyde cross-linking (61). (A) Structure of formaldehyde. 
(B) Two step of cross-linking chemistry of formaldehyde.  
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Figure 3.2 Cross-linking of AcrAS-His with increasing concentrations of formaldehyde. 
After 30 min incubation at room temperature in 20 mM Hepes-KOH (pH 7.0), NaCl 100 
mM, cross-linking was stopped by addition of 0.5 M glycine. The cross-linked AcrA was 
resolved by SDS-PAGE (8 %) and stained with silver nitrate. 
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        A                                          pH 7.0                                                             
                             
 
       B                                           pH 6.0 
                                
Figure 3.3 AcrAS-His formed oligomers in the presence of E. coli polar lipids. (A) FA 
was incubated with AcrAS-His in 20 mM Hepes (pH 7.0) buffers at various 
concentrations of lipids and NaCl. After termination of reactions by 0.5 M glycine, the 
cross-linked AcrAS-His were resolved by SDS-PAGE (8%) and stained with silver nitrate. 
(B) FA cross-linking of AcrAS-His in 20 mM Hepes (pH 6.0) buffers. Cross-linking was 
carried out as (A) except at pH 6.0. 
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NaCl for 30 minutes at room temperature. Cross-linking was terminated by addition of 
glycine at 0.5 M. Figure 3.2 shows the results of FA cross-linking of AcrAS-His. 
Consistent with previous hydrodynamic studies (72), no oligomers were detected in this 
AcrA. The band with the mobility higher than that of the denatured monomeric AcrAS-
His was detected at formaldehyde concentration above 0.03M. The amount of this band 
increased with the concentration of formaldehyde. The entire AcrA was cross-linked at 
formaldehyde concentration 1M. This observation implied that significant intra-molecular 
cross-linking occurred. In addition, when formaldehyde concentration was above 0.3 M, 
there was a band shift on SDS-PAGE, suggesting that high concentration of 
formaldehyde interferes with electrophoresis and makes data interpretation difficult. Thus, 
0.1-0.2 M formaldehyde was chosen in the subsequent experiments.  
             To examine the effect of E. coli polar lipids on the oligomerization of AcrAS-His, 
we incubated AcrAS-His with increasing concentrations of lipids before addition of 
formaldehyde. We did not detect AcrAS-His oligomers in 20 mM Hepes-KOH (pH 7.0) 
buffer containing lipids and 100 mM NaCl. However, when the final concentration of 
NaCl was reduced to 6.7 mM, AcrA oligomers could be detected in the presence of lipids. 
By comparison to the molecular weight markers, we determined that both dimers and 
trimers of AcrA could be detected under these conditions (Figure 3.3 A). This result 
indicated that AcrAS-His formed dimers and trimers in the presence of E. coli polar lipids.  
             As demonstrated in chapter 1, E. coli polar lipids phases affect the trypsin 
cleavage profile of AcrAL-His. Here we investigated whether the micelle to vesicle 
transition of lipids affect oligomerization of AcrAS-His. The concentration of TX was set 
constant at 3.2 mM. Before the FA cross-linking, purified AcrAL-His was incubated with 
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increasing concentrations of lipids from 1.3 mM to 13 mM. The molar ratios of 
lipids/Trtion X-100 were 1:2.5 (lipid micelles) and 4:1 (lipid vesicles) respectively. As 
showed in Figure 3.3 (A), significant oligomers of AcrAS-His were detected in the 
presence of both lipid vesicles and lipid micelles. This result suggests that lipid bilayers 
are not required for the oligomerization of AcrAS-His.  
             Given that pH in the periplasm is about 6.0  (36), formaldehyde cross-linking was 
also carried out at pH 6.0. Results shown in Figure 3.3 (B) demonstrated that similar to 
pH 7.0 condition, AcrAS-His formed oligomers at pH 6.0, indicating that pH does not 
affect the oligomerization of AcrAS-His in vitro.  
 
3.2 NaCl affects the oligomerization of AcrAS-His in vitro 
            To analyze the effect of NaCl in more detail and further elucidate the 
oligomerization mechanism of AcrAS-His, we performed formaldehyde cross-linking of 
AcrAS-His at various concentrations of NaCl (Figure 3.4). When NaCl concentration 
increased from 6.7 mM to 60 mM, there was no significant change in AcrAS-His 
oligomerization. However, no oligomerization was detected when NaCl concentration 
increased to 100 mM, indicating that high concentration of NaCl inhibits AcrAS-His 
oligomerization. This result also suggested that the electrostatic interaction might be 
involved in AcrA-lipid interactions.  
             In summary, formaldehyde cross-linking results demonstrated that AcrAS-His can 
form oligomers in the presence of E. coli polar lipids. Hence AcrA-lipid interaction 
promotes oligomerization of AcrAS-His.  
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Figure 3.4 Oligomerization of AcrAS-His is inhibited by 100 mM NaCl. AcrAS-His was 
incubated with FA in 20 mM Hepes (pH 7.0) buffer containing increasing concentrations 
of NaCl (6.7 mM, 15 mM, 30 mM, 60 mM, and 100 mM). Reactions were terminated by 
addition of glycine (0.5 M). Cross-linked AcrAS-His was resolved by SDS-PAGE (8%) 
and stained with silver nitrate. 
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3.3 Investigation of AcrAL-His oligomerization by chemical cross-linking  
            Oligomerization of AcrAL-His was investigated using formaldehyde cross-linking 
as described above for AcrAS-His. Figure 3.5 (A) shows the results of cross-linking of 
AcrAL-His with increasing concentrations of formaldehyde. At a formaldehyde 
concentration of 0.01 M, intra-molecular cross-linking was observed. As formaldehyde 
concentration was increased to 0.03 M, we detected oligomers (dimers and trimers) of 
AcrAL-His. This result is different from the monomeric AcrAS-His. Lipid modification at 
the N-terminus thus promotes the oligomerization of AcrA. Besides, we also found 
additional bands above trimer, indicating that there were some high-order oligomers. The 
time course of formaldehyde incubation with AcrAL-His was also studied (Figure 3.5 B). 
As expected, at 0.1 M formaldehyde, AcrAL-His was cross-linked into dimers and trimers 
even after 10 min of incubation. The amount of higher molecular weight bands increased 
with time of incubation. Overnight incubation with FA caused over-crosslinking of 
proteins without any clear bands. Once formaldehyde concentration was increased to 0.3 
M and higher, the amount of high molecular weight bands increased. All these results 
demonstrated that AcrAL-His exists as oligomers in solution.  
             Unlike the effect of NaCl on oligomerization of AcrAS-His, AcrAL-His cross-
linking in vitro was not affected by NaCl concentrations (Figure 3.6). In addition, 3.2 mM 
TX did not completely dissociate the AcrAL-His oligomers.  
            Since the lipid bilayers change the tryptic cleavage of AcrAL-His (Figure 1.9), we 
also investigated the effect of lipids on oligomerization of AcrAL-His (Figure 3.6). Cross-
linking profiles did not change significantly when the lipid concentration increased from 
1 mM  (mixed micelle)  to  10 mM  (vesicles), suggesting  that  lipids  do not  affect  the  
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Figure 3.5 Cross-linking of AcrAL-His with increasing concentrations of formaldehyde. 
(A) After 30 min incubation of AcrAL-His with FA, cross-linking was terminated with 
glycine (0.5 M). The cross-linked AcrA was resolved by SDS-PAGE (8%). (B) Time 
course of formaldehyde cross-linking of AcrAL-His in vitro. AcrAL-His was incubated 
with FA (0.1 M, 0.3 M, and 1.0 M) for 10, 30, 90 minutes and overnight. Cross-linking 
was terminated with glycine (0.5 M). The cross-linked AcrAL-His was resolved by SDS-
PAGE (8%).   
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Figure 3.6 Formaldehyde cross-linking of AcrAL-His in vitro. FA was incubated with 
AcrAL-His for 30 min in 20 mM Hepes (pH 7.0) buffer containing 3.2 mM TX and 
increasing concentrations of E. coli polar lipids and NaCl. After termination by addition 
of 0.5 M glycine, cross-linked products were analyzed by 8% SDS-PAGE followed by 
silver nitrate staining.  
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oligomerization of AcrAL-His. Taken together, our results showed that lipid modification 
stabilizes the association of AcrAL-His protomers.  
 
3.4 Characterization of AcrAL-His oligomers by size exclusion chromatography 
            To characterize AcrA oligomerization, the molecular weight of AcrA was 
determined using size exclusion chromatography (SEC) coupled with static light 
scattering (SLS) and refractive index (RI) detectors. Size exclusion chromatography 
separates fragments on the basis of the molecular weight, whereas combination of static 
light scattering and refractive index allow to measure molecular weights of protein in 
solution.  
            Table 3.1 shows the calculated from a.a. composition and measured molecular 
weights of size markers. The measured molecular weight of amylase is about 190 kDa, 
slightly less than the calculated value 200 kDa. The measured molecular weight of BSA 
is about 72 kDa, a little larger than the theoretical value of 66.7 kDa. The measured 
molecular weight (30 kDa) of carbonic anhydrase is also very close to the calculated 
number (29 kDa). The differences between calculated and theoretical values in three 
proteins are within 10%.  
             AcrAL-His was applied onto SEC column followed by SLS and RI in sequence.  
The three chromatography profiles are shown on Figure 3.7. The UV absorption showed 
that AcrAL-His is separated into two peaks, peak 1 and peak 2. Combination of SLS and 
RI was used to calculate the molecular weights of proteins in these peaks. Table 3.2 
demonstrated that peak 1 contains a protein with the molecular weight 436 ± 27 kDa, 
whereas  peak 2  contains a protein with  the  molecular weight 128 ± 6 kDa.  This   result  
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Table 3.1 Molecular weights of standard markers measured by LS/SEC  
Proteins 
Mw(Cal.) 
(Dalton) 
Mw* 
(Dalton) 
Mn* 
(Dalton) Mw/Mn 
Mp* 
(Dalton) 
Amy 200K 189100 188900 1.001 188400 
BSA 66.7K 71720 71670 1.001 71610 
CA 29K 29960 29760 1.007 31620 
 
Note: 1. “Cal” is for calculated (from amino acid sequences) values. 
           2. Three molecular weight averages are defined as (35) 
             
             
              Mp* is the molecular weight of the peak 
 
In which, Mi stands for the molecular weight of ith molecules, Ni is the number of ith 
molecules with MW Mi.  
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Figure 3.7 Size exclusion chromatography, refractive index profile, and light-scattering 
profile of AcrAL-His. The primary Y-axis (left) is for SEC and RI, and secondary Y-axis 
(right) is for SLS. The flow rate of SEC was set at 1.0 ml/min. The running buffer 
contained 20 mM Tris-HCl (pH 7.0), NaCl 300 mM, and DDM (0.05%, w/v). 50 µg of 
AcrA (0.5 mg/ml) was loaded onto Diol-300 (YMC) column.  
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Table 3.2 Molecular weights of AcrAL-His measured by LS/SEC 
 
Mw 
(Dalton) 
Mn 
(Dalton) Mw/Mn 
Mp 
(Dalton) 
peak 1 
    
1st Trial 
407800 407600 1.001 412100 
2nd Trial 
461400 460700 1.001 467700 
3rd Trial 
439000 438900 1.000 436500 
average 
436067 435733 1.001 438767 
peak 2     
1st Trial 128600 128600 1.000 125900 
2nd Trial 120400 120300 1.000 118900 
3rd Trial 136300 136200 1.000 133400 
average 128433 128367 1.000 126067 
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Figure 3.8 Fraction collection of AcrAL-His separated by size exclusion chromatography. 
(A) Size exclusion chromatography of AcrAL-His. Y axis is the UV absorption at 280 nm, 
and X-axis is time in min. The flow rate was set at 1.0 ml/min. (B) SDS-PAGE (12%) 
analysis of AcrAL-His fractions separated by size exclusion chromatography. The 
numbers on the top of the SDS-PAGE are elution times in min.  
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suggested that peak 1 contains high-order oligomers of AcrA and peak 2 contains AcrA 
trimers. Previously AcrA trimers were detected in the in vivo DSG cross-linking 
experiment (74). The amount of AcrA in peak 2 (trimers) is much larger than that of peak 
1 (high-order oligomers), we therefore concluded that AcrAL-His exists as an oligomer, 
mostly a trimer in vitro. 
            To confirm that the peaks in the SEC profiles contain AcrA protein, fractions 
(0.25ml/aliquot) were collected under the same condition (Figure 3.8). The first peak was 
eluted from 9th min to 10.5th min. The amount of the second peak reached the top 
concentration at 11.5th min and then slowly decreased until 17th min. The silver staining 
of SDS-PAGE (12%) of the fraction collection is shown on Figure 3.8 (B). The profile 
suggests that the peaks in the UV absorption (280 nm) correspond to AcrA proteins rather 
than other contaminations. In addition, a 2-fold decrease of the loading amount of AcrAL-
His did not affect the separation results (data not shown). Moreover, similar results were 
obtained with two other independent AcrA preparations (data not shown). Thus, above 
consistent results suggest that lipidated AcrA form a stable oligomer.  
 
3.5 Characterization of soluble forms of AcrA by size exclusion chromatography 
            When AcrAS-His was applied onto SEC, we detected several small peaks from 6th 
min to 16th min (Figure 3.9, A). However, the collected fractions did not contain proteins. 
As shown on Figure 3.9 (B), AcrAS-His was eluted from the column after 18th min. 
Moreover, there were two peaks in the UV (280 nm) absorption profile. Since Diol-300 
column has a specific separation range (10 kDa to several 100 kDa) and volume (15 ml), 
samples eluted at 15 min (flow rate: 1 ml/min) represent the included volume of the 
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column. The molecular weight of AcrA monomer is 41 kDa, which is within the 
separation range of Diol-300 column. We concluded that the abnormal chromatography 
of non-lipidated AcrAS-His is likely due to non-specific binding of AcrAS-His to column 
matrix.  
              Since the Diol-300 column could not be used to characterize the purified AcrAS-
His which is translocated into the periplasm with the aid of the cleavable signal peptide, 
we used the soluble form of mature AcrA-His. This soluble form of AcrA-His (AcrAC-
His, superscript C is for cytoplasmic) does not contain a signal peptide and is expressed 
in the cytoplasm. AcrAC-His was purified as described previously (40). As shown on 
Figure 3.10, This AcrAC-His was eluted at 13th min. The MW analysis showed that this 
AcrAC-His exists as a monomer (41 kDa) in solution.  
              Together, our FA cross-linking experiment showed the monomeric state of 
purified AcrAS-His in solution. This result is in agreement with the hydrodynamic study 
(72). However, this AcrAS-His can form oligomers in the presence of E. coli polar lipids, 
suggesting that the interaction between AcrA and lipids is one of the driving forces of 
oligomerization of AcrAS-His. On the other hand, our study, especially the SEC result, 
demonstrated that AcrAL-His exists as an oligomer, mostly a trimer, in vitro. This result 
indicates that lipid modification at the N-terminal Cys residue stabilizes the AcrAL-His 
oligomers. We concluded that AcrA functions as a trimer inside the cell.  
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B 
           
Figure 3.9 Fraction collection of AcrAS-His separated by size exclusion chromatography. 
(A) Size exclusion chromatography of AcrAS-His. Y axis is the UV absorption at 280 nm, 
and X-axis is time in min. The flow rate was set at 1.0 ml/min. (B) SDS-PAGE (12%) 
analysis of AcrAS-His separated by size exclusion chromatography. The numbers on the 
top of the SDS-PAGE are elution times in min. 
89 
 
 
 
 
 
 
 
Figure 3.10 Size exclusion chromatography of purified cytoplasmic AcrAS. Y axis is the 
UV absorption at 280 nm, and X-axis is time in min. The flow rate was set at 1.0 ml/min.  
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Chapter 4 Discussion 
 
4.1 Lipid modification and lipid bilayer association affect the proteolytic 
accessibility of AcrA  
            Using limited proteolysis, we demonstrated that lipid modification and association 
of AcrAL-His with lipid bilayers affect the accessibility of AcrA to proteases. In particular, 
different tryptic digestion profiles between AcrAS-His and AcrAL-His suggested that the 
lipid modification affects the accessibility of AcrA to trypsin. For example, R315 in 
AcrAL-His is less accessible than that of AcrAS-His. In addition, E. coli polar lipid 
vesicles cause changes of the accessibility of AcrAL-His to trypsin. 
             AcrA is cleaved by trypsin into several fragments and the cleavage sites are 
located in the N- and C-terminal domains of AcrA which are folded together into the MP 
domain (Figure 1.6). The N-terminal strand directly passes through this MP domain, 
whereas the C-terminal residues form an up-down-up β-sheet. Structural model of the MP 
domain in AcrA shows that the cleavage site T47 is located on the loop between β-1 and 
β-2 strands (Figure 1.6). Cleavage sites R315 and K346 are positioned on the strand β-16 
and the loop between β-18 and β-19 strands respectively. Another cleavage site K374 is 
located at the end of the MP domain and is exposed to external medium. During the 
tryptic digestion of AcrAS-His and AcrAL-His, the 32.1 kDa fragment (T47-K346) and 
28.9 kDa fragment (T47-R315) are accumulated. However, the time course showed that 
these two fragments are formed with different kinetics depending on the presence of lipid 
modification. Compared to AcrAS-His, the accumulation of the 32.1 kDa fragment (T47-
K346) and the slower formation of the 28.9 kDa fragment (T47-R315) in AcrAL-His 
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indicated that lipid moiety at the N-terminus of AcrA protects the residue R315 from 
trypsin cleavage, which results in the rapid accumulation of the 32.1 kDa fragment (T47-
K346).   
            When AcrAL-His binds to lipid bilayers, some amount of intact AcrAL-His are not 
cleaved by trypsin. This indicates that the MP domain of AcrA is protected by lipid 
bilayers. In the periplasm the MP domain is proposed to be adjacent to the inner 
membrane. The association of AcrA, especially the MP domain, with lipid bilayers 
inhibits the access of these sites to trypsin. Thus the protection of the MP domain by lipid 
bilayers causes this trypsin-resistance. 
            In addition, the decrease in the amounts of the 32.1 kDa fragment (T47-K346) 
and increase of the 28.9 kDa fragment (T47-R315) in AcrAL-His are coupled with the 
transition from lipid micelles to vesicles. This result suggests that R315 in AcrAL-His 
becomes more accessible and/or flexible once lipid bilayers are introduced. One 
explanation is that association of AcrAL-His with lipid bilayers induces the 
conformational changes of residue R315 on the β-16 strand of the MP domain, causing 
more exposure of R315 to external medium. The other interpretation is the steric 
hindrance of the N-terminal lipid modification. In this case, cleavage site R315, on the 
convex face of the MP domain, is masked by lipid moiety/modification in solution. 
Association of AcrAL-His with lipid bilayers results in the insertion of the N-terminal 
lipid moiety into lipid bilayers, by which the mask effect of lipid moiety on R315 is 
decreased and thus R315 is more liable to be cleaved by trypsin.  
            Since the 32.1 kDa fragment (T47-K346) is the intermediate product during the 
trypsin proteolysis, the decreased amount of the 32.1 kDa fragment (T47-K346) in the 
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presence of lipid bilayers can be explained by the faster further cleavage to produce the 
stable 28.9 kDa fragment (T47-R315). Another interpretation is that the accessibility of 
K346 on the flexible loop (between β-18 and β-19 strands) of the MP domain is 
decreased due to the structural variations induced by lipid bilayers. Although association 
of AcrAL-His with lipid bilayers affects the trypsin accessibility at R315 and K346, other 
experiments are needed to further investigate the effect of the lipid modification 
interference on the tryptic digestion of AcrAL-His. 
            In conclusion, our results demonstrate that lipid modification results in the 
decrease of the accessibility of R315 to proteases, possibly due to the protection by the 
lipid moiety or structural changes in the β-16 strand of the MP domain. Association of 
AcrAL-His with lipid bilayers increases the accessibility of R315 by decreasing the steric 
hindrance or conformational variations. On the other hand, the decrease of the 32.1 kDa 
fragment (T47-K346) in the presence of lipid bilayers indicates that this fragment is 
rapidly cleaved to form the stable 28.9 kDa core (T47-R315) or the accessibility of the 
cleavage site K346, located on the flexible loop of the MP domain, is decreased due to 
steric hindrance of lipid bilayers or the structural changes in AcrA.  
 
4.2 The MP domain of AcrA is protected in the AcrAB-TolC complex 
            AcrA-AcrB-TolC is a stable multidrug efflux complex and the substrates do not 
affect the complex assembly in vivo (66, 67). Several lines of evidence have shown that, 
as a periplasmic adaptor protein, AcrA bridges AcrB and TolC to form the stable complex 
(32, 62, 67). Using the in vivo cross-linking and the structural modeling, Symmons et al 
proposed that the lipoyl domain, β-barrel, and MP domain of AcrA associate with AcrB, 
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whereas the α-helical haripin of AcrA is involved in the interaction with TolC (62). Our in 
vitro proteolysis experiments showed that the MP domain of the purified AcrA is flexible 
and rapidly cleaved by trypsin. Therefore we examined the tryptic profiles of AcrA in 
vivo in the presence and absence of AcrB and TolC. The overexpressed from plasmid 
AcrA was cleaved in vivo into the same set of fragments as in vitro. However, the 
proteolytic profiles of chromosomal AcrA depended on the genetic background of E. coli 
strains. Our result showed that the deletion of any of the two components AcrB or TolC 
results in the tryptic cleavage of AcrA, which is different from that in the functional 
tripartite complex. In particular, the 28.9 kDa fragment (T47-R315) was not detected but 
the 26.5 kDa fragment (T47-R294 or T47-R296) was accumulated in the AG100 (WT) 
cells in which the functional tripartite complex is formed. In contrast, both fragments 
were formed and then rapidly cleaved in the cells AG102MB and ZK796, in which AcrA 
associates with either TolC or AcrB, respectively (Figure 2.2). On the other hand, 
expression of the respective missing component AcrB or TolC from plasmids introduced 
into AG102MB (∆AcrB) or ZK796 (∆TolC) cells, correspondingly, restored the tryptic 
cleavage profile of AcrA as in the tripartite complex. This result suggests that the MP 
domain of AcrA is protected when the functional multidrug efflux complex AcrAB-TolC 
is assembled.   
            Furthermore, the lack of the 28.9 kDa fragment (T47-R315) in AG100 cells (WT) 
can be explained by the protection of R315. In the structural modeling of AcrA, R315 is 
located on the β-16 strand. Thus, the assembly of the tripartite complex AcrAB-TolC 
causes the change of accessibility of the β-16 strand, at least the burial of the residue 
R315. This residue is adjacent to the residue D320 which was reported to be directly 
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cross-linked to AcrB (62). On the other hand, the assembly of the tripartite complex also 
prevents the 26.5 kDa fragment (T47-R294 or T47-R296) from further digestion. 
Moreover, the 36.9 kDa fragment (Q29-K374) is accumulated in AG100 (WT) but further 
cleaved in AG102MB (∆AcrB) and ZK796 (∆TolC). Our structural model of AcrA 
including the MP domain shows that the cleavage site (R294 or R296) is located at the 
end of α-β-barrel domain, which is linked to the MP domain by a short β-linker, whereas 
another cleavage site K374 terminates the MP domain. Therefore the MP domain is 
folded as an integrated domain and protected in the functional tripartite complex.  
            In the docking model of the AcrAB-TolC complex (62), these cleavage sites in 
AcrA (R294/R296, R315, and K374) are adjacent to the AcrA-AcrB interfaces (PC1 and 
PN2 domains in AcrB). It is likely that the functional assembly of the tripartite complex 
rather than bipartite complexes (AcrA-AcrB and AcrA-TolC) in vivo induces the folding 
changes in the MP domain of AcrA, which protect this domain from trypsin attack.  
            Furthermore, the functional study shows that the MP domain is essential for the 
drug efflux in E. coli (12). Dr. Yoichi Yamada performed the site-specific mutagenesis on 
the conserved twelve residues in the MP domain. The MIC data showed that one AcrA 
mutant, G363C, significantly impaired the drug efflux activity by AcrAB-TolC pump. 
Although the reason for the functional defect in G363C is still unclear, it is likely that 
G363C causes the structural defect in the assembled tripartite complex. The failure of the 
complex assembly due to this substitution is supported by the tryptic cleavage profile of 
this mutant which was similar to that of overproduced AcrA-His in the absence of AcrB. 
Indeed, previously Krishnamoorthy et al demonstrated that the misfit between 
components of the tripartite complex impaired the drug efflux function (29).  
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Figure 4.1 Schematic representation of the mechanism of assembly of AcrAB-TolC 
complex. The lipoyl and β-barrel domains of AcrA interact with AcrB, whereas the α-
helical hairpin docks against TolC. In the bi-partite complexes, the MP domain is 
unstructured and readily cleaved by trypsin. However, upon assembly of the functional 
tri-partite AcrAB-TolC complex this domain is trypsin-resistant.  
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            Taken together, above results suggest that the MP domain of AcrA is required for 
the functional assembly of AcrAB-TolC complex. Moreover, the lack of the 28.9 kDa 
fragment (T47-R315) and the accumulation of the 36.9 kDa (Q29-K374) and 26.5 kDa 
(T47-R294/R296) fragments in the trypsin digestion of AcrA assembled into the 
functional complex indicates that, compared to either AcrA-AcrB or AcrA-TolC bipartite 
complexes, the MP domain of AcrA is structured and resists the further digestion in the 
functional tripartite complex (Figure 4.1).  
 
4.3 AcrA forms oligomers in vitro 
            Oligomerization of AcrA is a controversial issue. Monomer, dimer, trimer, and 
dimer of dimers have been proposed in different studies (2, 40, 72, 74). In particular, 
AcrAS-His is a monomer in solution, whereas it forms oligomers in vivo (74). Using 
chemical cross-linking, we found that monomeric AcrAS-His forms oligomers in the 
presence of E. coli polar lipids. Thus AcrA-lipid interaction promotes AcrAS-His 
oligomerization. This also provides the interpretation for the purified AcrAS-His existing 
as a monomer in solution but forming oligomers in vivo (72, 74). It should be noted that 
low concentration of NaCl (less than 100 mM) is also necessary for AcrAS-His 
oligomerization in solution. Indeed, the in vitro formed AcrAS-His oligomers dissociated 
into monomers again when NaCl concentration was increased to 100 mM, which explains 
why AcrAS-His exist as monomers in solution containing high concentrations of NaCl 
(more than 100 mM). This result also suggests that other factors are required for the 
oligomerization of AcrAS-His in vivo.  
            Lipidated AcrAL-His, on the other hand, was reported to form oligomers in vivo 
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(74). Interestingly, we found that unlike the monomeric AcrAS-His, AcrAL-His exists as 
an oligomer in solution. This result strongly indicates that lipid modification stabilizes 
the AcrA oligomers in vitro. Unlike the weak interaction among AcrAS-His protomers, 
AcrAL-His protomers form stable oligomers, even in the presence of mild detergents such 
as TX and DDM. The proteolytic profile of the oligomeric AcrAL-His is similar to that of 
monomeric AcrAS-His. This result suggests that oligomerization does not protect the MP 
domain of AcrA from trypsin attack. This in turn indicates that oligomerization of AcrA 
involves other domains of AcrA. In the crystal structure of AcrA core, there are intensive 
contacts involving the α-helical hairpin, lipoyl domain and α-β-barrel domain in the 
parallel association of AcrA dimers (40).   
            In the SEC experiment, we detected and identified two forms of AcrA oligomers. 
The major peak contains AcrA trimers, whereas the second peak contains high-order 
oligomers in which there are about 10-12 AcrA protomers. The amount of AcrA trimers is 
much larger than that of the high-order oligomers as shown in Figure 3.7. This result is 
consistent with the previous in vivo cross-linking study, which showed that AcrA trimers 
is the predominant form of AcrA in vivo (74). The high-order AcrA oligomers are likely 
to be protein aggregates. We noticed that the amount of AcrA in this peak increases with 
time.   
            On the other hand, dimers of AcrA were detected in our formaldehyde cross-
linking experiments (Figure 3.3) and the previous DSG cross-linking study (74). Since 
the chemical cross-linking is time dependent, the dimers of AcrA possibly represent 
intermediate products of the reaction.  
            In the crystal structure, AcrA is a dimer of dimer. However, this structure contains 
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only the core of AcrA (45-312 a.a). This dimer of dimer arrangement possibly does not 
reflect the oligomerization of the whole AcrA protein. Indeed, MexA, AcrA homolog in P. 
aeruginosa, was crystallized as a whole protein molecule (21, 62). MexA protomers 
associate to form unusual six- and seven-membered superhelical rings in a head-to-head 
manner. In this crystal structure, the MP domain was not structured in most MexA 
protomers, but in some protomers (for example, B and F chain) was crystallized and 
resolved (62). Inter-molecular hydrogen-bond network is involved in the formation of the 
wide part of the funnel structure, whereas the narrow (central) part consists of the 
conventional coiled-coils (21).  
            Taken together, our study shows that lipid modification and AcrA-lipid are 
involved in the oligomerization of AcrA. Our results, especially SEC data, suggest that 
AcrA forms oligomers, mostly trimers. Although we have found that lipid modification 
contributes to the oligomerization of AcrA, we still don’t know how lipid modification at 
the N-terminal Cys residue can affect the oligomerization of AcrA. One possibility is that 
lipid modification stabilizes the MP domain, which is required for the oligomerization of 
AcrA. In addition, it remains unclear: what is the oligomeric number of AcrA in vivo? 
How do these AcrA oligomers form and cooperate with AcrB and TolC to assemble a 
functional tripartite complex? Answering these questions in the future will further 
improve our understanding of the molecular mechanism of AcrAB-TolC complex 
assembly.  
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Appendix 1 
 
Abbreviations 
 
ABC                              ATP Binding Cassette 
BSA                              Bovine Serum Albumin  
CA                              Carbonic Anhydrase  
CBB Coomassie Brilliant Blue  
DDM n-Dodecyl-β-D-Maltoside  
DTT Dithiothreitol  
EDTA                         Ethylenediaminetetraacetate  
F5M                            Fluorescein-5-Maleimide  
FA Formaldehyde  
HEPES N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid  
IM Inner Membrane  
IPTG                         Isopropyl-β-D-thiogalactopyranoside  
kDa                               Kilodalton  
LB Luria-Bertani  
LS                           Light Scattering 
MALDI-TOF                
 
Matrix-Assisted Laser Desorption/Ionization coupled 
Time-Of-Flight  
MATE                        Multidrug And Toxic Compound Extrusion 
MFP  Membrane Fusion Protein 
MFS Major Facilitator Superfamily 
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MIC Minimal Inhibitory Concentration 
MS Mass Spectrometry  
MW Molecular Weight 
OD Optical Density 
OM Outer Membrane 
OMF Outer Membrane Factor  
ORF Open Reading Frame 
PBS Phosphate Buffered Saline 
PK Proteinase K                
PL Proteoliposomes  
POE Polyoxyethylene 
PMSF Phenylmethylsulfonyl fluoride 
RI Refractive Index 
RND Resistance-Nodulation-Cell Division  
RT Room Temperature  
SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis 
SEC Size Exclusion Chromatography  
SMR Small Multidrug Resistance  
TX Triton X-100 
UV Ultraviolet 
WT                               Wild type 
 
